<SUBMISSION>
<ACCESSION-NUMBER>0001140361-07-016410
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20070814
<ITEMS>2.02
<ITEMS>9.01
<FILING-DATE>20070814
<DATE-OF-FILING-DATE-CHANGE>20070814
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>BIOSANTE PHARMACEUTICALS INC
<CIK>0001023024
<ASSIGNED-SIC>2836
<IRS-NUMBER>582301143
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-31812
<FILM-NUMBER>071056127
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>111 BARCLAY BLVD STE 280
<CITY>LINCOLNSHIRE
<STATE>IL
<ZIP>60069
<PHONE>8474780500
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>111 BARCLAY BLVD STE 280
<CITY>LINCOLNSHIRE
<STATE>IL
<ZIP>60069
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>BEN ABRAHAM TECHNOLOGIES INC
<DATE-CHANGED>19991027
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>q120078k.htm
<DESCRIPTION>BIOSANTE 8K FOR 6-30-07
<TEXT>
<html>

  <head>
    <title>q120078k.htm</title>
<!-- Licensed to: EDGARfilings, Ltd.-->
<!-- Document Created using EDGARizer 4.0.1.0 -->
<!-- Copyright 2007 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;"><strong>UNITED
        STATES</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;"><strong>SECURITIES
        AND EXCHANGE COMMISSION</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Washington,
        D.C.&#160;&#160;20549</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">__________________</font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman;"><strong>FORM
        8-K</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Current
        Report</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Pursuant
        to Section 13 or 15(d) of the Securities Exchange Act of
        1934</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">__________________</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Date
        of
        Report (Date of earliest event reported):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>August
        14, 2007</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman;"><strong>BIOSANTE
        PHARMACEUTICALS, INC.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">(Exact
        name of registrant as specified in its charter)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td valign="top" width="27%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;"><strong>Delaware</strong></font></div>
              </td>
              <td valign="top" width="27%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;"><strong>001-31812</strong></font></div>
              </td>
              <td valign="top" width="27%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;"><strong>58-2301143</strong></font></div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="27%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">(State
                  or Other Jurisdiction of Incorporation)</font></div>
              </td>
              <td valign="top" width="27%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">(Commission
                  File Number)</font></div>
              </td>
              <td valign="top" width="27%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">(I.R.S.
                  Employer Identification Number)</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td valign="top" width="40%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;"><strong>111
                  Barclay Boulevard</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;"><strong>Lincolnshire,
                  Illinois</strong></font></div>
              </td>
              <td valign="top" width="40%">
                <div>&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;"><strong>60069</strong></font></div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="40%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">(Address
                  of Principal Executive Offices)</font></div>
              </td>
              <td valign="top" width="40%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">(Zip
                  Code)</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>(847)
        478-0500</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">(Registrant&#8217;s
        Telephone Number, Including Area Code)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>N/A</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">(Former
        Name or Former Address, If Changed Since Last Report)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Check
        the
        appropriate box below if the Form 8-K filing is intended to simultaneously
        satisfy the filing obligation of the registrant under any of the following
        provisions:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top">
              <td align="right" style="WIDTH: 36pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Wingdings 2, serif">&#163;&#160;&#160;</font></div>
              </td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Written
                  communications pursuant to Rule 425 under the Securities Act (17
                  CFR
                  230.425)</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top">
              <td align="right" style="WIDTH: 36pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Wingdings 2, serif">&#163;&#160;&#160;</font></div>
              </td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Soliciting
                  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
                  240.14a-12)</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top">
              <td align="right" style="WIDTH: 36pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Wingdings 2, serif">&#163;&#160;&#160;</font></div>
              </td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Pre-commencement
                  communications pursuant to Rule 14d-2(b) under the Exchange Act
                  (17 CFR
                  240.14d-2(b))</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" id="list" width="100%">

            <tr valign="top">
              <td align="right" style="WIDTH: 36pt">
                <div><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Wingdings 2, serif">&#163;&#160;&#160;</font></div>
              </td>
              <td>
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Pre-commencement
                  communications pursuant to Rule 13e-4(c) under the Exchange Act
                  (17 CFR
                  240.13e-4(c))</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div>&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Section
        2 &#8211; Financial Information</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Item
        2.02. Results of Operations and Financial Condition</strong>.</font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">On
        August
        14, 2007, BioSante Pharmaceuticals, Inc. publicly announced its financial
        results for the second quarter ended June 30, 2007.&#160;&#160;For further
        information, please refer to the press release attached hereto as Exhibit
        99.1,
        which is incorporated by reference herein.</font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">The
        information contained in this Item 2.02 and Exhibit 99.1 hereto shall not
        be
        deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act
        of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability
        of that section, and shall not be incorporated by reference into any filings
        made by BioSante Pharmaceuticals, Inc. under the Securities Act of 1933,
        as
        amended, or the Exchange Act, except as may be expressly set forth by specific
        reference in such filing.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Section
        9 &#8211; Financial Statements and Exhibits</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Item
        9.01. Financial Statements and Exhibits.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<em>Exhibits</em>.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">Exhibit
                    No.</font></div>
                </div>
              </td>
              <td valign="top" width="59%" style="BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">Description</font></div>
                </div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="10%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">99.1</font></div>
              </td>
              <td align="justify" valign="top" width="59%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">Press
                  Release issued August 14, 2007</font></div>
              </td>
            </tr>

        </table>
      </div><br>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div><br>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>SIGNATURE</strong></font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Pursuant
        to the requirements of the Securities Exchange Act of 1934, the registrant
        has
        duly caused this report to be signed on its behalf by the undersigned hereunto
        duly authorized.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 216pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>BIOSANTE
        PHARMACEUTICALS, INC.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 216pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">By:<u>&#160;&#160;/s/
        Phillip B. Donenberg</u></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 234pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Phillip
        B. Donenberg</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 234pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><em>Chief
        Financial Officer, Treasurer and Secretary</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Dated:&#160;&#160;<strong>&#160;</strong>August
        14, 2007</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>BIOSANTE
        PHARMACEUTICALS, INC.</strong></font></div>
      <div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>FORM
        8-K</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong><u>Exhibit
        Index</u></strong></font></div>
      <div><br></div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;"><strong>Exhibit
                    No.</strong></font></div>
                </div>
              </td>
              <td valign="bottom" width="41%" style="BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;"><strong>Description</strong></font></div>
                </div>
              </td>
              <td valign="bottom" width="25%" style="BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;"><strong>Method
                    of Filing</strong></font></div>
                </div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="11%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">99.1</font></div>
              </td>
              <td align="justify" valign="top" width="41%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">Press
                  Release issued August 14, 2007</font></div>
              </td>
              <td valign="top" width="25%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman;">Furnished
                  herewith</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div><br></div>
    </div>
  </body>
</html>



</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pressrelease8-14.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>

  <head>
    <title>pressrelease8-14.htm</title>
<!-- Licensed to: EDGARfilings, Ltd.-->
<!-- Document Created using EDGARizer 4.0.1.0 -->
<!-- Copyright 2007 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><img src="biosantelogo6.jpg" alt=""></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>BioSante
        Pharmaceuticals, Inc.</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">111
        Barclay Boulevard</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Lincolnshire,
        Illinois 60069</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">www.biosantepharma.com</font></div>
    </div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>FOR
      IMMEDIATE
      RELEASE&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>Amex:
      BPA</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;"><strong>BioSante
      Pharmaceuticals Reports</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman;"><strong>Second
      Quarter 2007 Financial Results</strong></font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>LINCOLNSHIRE,
      Illinois - (</strong><strong>August 14</strong><strong>, 2007)</strong> ---
      BioSante Pharmaceuticals, Inc. (AMEX: BPA) today reported its June 30, 2007
      cash
      balance and its financial results for the second quarter and six months ended
      June 30, 2007.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">The
      Company&#8217;s cash, cash equivalents and short-term investments as of June 30, 2007
      were approximately $31.3 million, as compared to approximately $11.5 million
      on
      December 31, 2006.&#160;&#160;The increase in cash is due to the private
      placement of 3,054,999 shares of common stock at a purchase price of $6.00
      per
      share.&#160;&#160;The placement included, for each share purchased, a warrant to
      purchase 0.25 shares of common stock at an exercise price of
      $8.00.&#160;&#160;The net proceeds from this placement were approximately $17.3
      million.&#160;&#160;The Company&#8217;s cash burn rate is expected to increase in the
      second half of 2007 to approximately $850,000 per month as its LibiGel<font style="DISPLAY: inline; FONT-SIZE: 10pt;"><sup>&#174;</sup></font> program
      progresses.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">BioSante
      incurred a net loss of approximately $2.4 million or ($0.10) per share for
      the
      quarter ended June 30, 2007 and $4.2 million or ($0.18) per share for the six
      months ended&#160;June 30, 2007, compared to a net loss of $2.2 million or
      ($0.17) per share and $5.5 million or ($0.28) per share for the same periods
      in
      2006.&#160;&#160;This decrease was due primarily to a reduction in business
      development and legal expenses and a decrease in non-cash stock-based
      compensation expense.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong><u>Recent
      </u><u>Product Development </u><u>Highlights</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong><u>Hormone
      Therapy</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">In
      June
      2007, Elestrin&#8482; (estradiol gel) was launched in the U.S. for the treatment of
      hot flashes by Bradley Pharmaceuticals, Inc. (NYSE:BDY), BioSante&#8217;s U.S.
      marketing licensee.&#160;&#160;Elestrin was approved by the U.S. Food and Drug
      Administration (FDA) in December 2006.&#160;&#160;Upon execution of the
      marketing agreement with Bradley in November 2006, BioSante received $3.5
      million.&#160;&#160;The December FDA approval triggered a payment of $10.5
      million to BioSante.&#160;&#160;In March 2007, the Company received $7.0 million
      of this payment with the balance to be received by year-end
      2007.&#160;Sales-based milestone payments could bring payments from Bradley to
      BioSante up to an additional $40 million over several years.&#160;In addition,
      Bradley has agreed to pay to BioSante royalties on sales of
      Elestrin.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Also
      in
      June 2007, the Company announced that it and a subsidiary of Teva Pharmaceutical
      Industries Ltd., will reinitiate their development of a male testosterone
      therapy product for the U.S. market.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">In
      May
      2007, the Company announced an exclusive license agreement with Pantarhei
      Bioscience for the development and marketing of an oral contraceptive in the
      United States.&#160;&#160;In June 2007, the Company announced that it and
      Pantarhei have begun a Phase II clinical trial of an oral
      contraceptive.&#160;&#160;The Phase II study, being conducted in the
      Netherlands, will include approximately 72 women in a double-blind, placebo
      controlled, randomized, comparative 2-way crossover study to determine the
      effect of a new patented oral contraceptive on sexual arousability and the
      vascular component of the sexual arousal response in women.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong><u>Calcium
      Phosphate Nanotechnology</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">In
      July
      2007, the Company announced new positive results for its <font style="DISPLAY: inline; FONT-SIZE: 10pt;">calcium phosphate
      nanotechnology</font>&#160;(CaP) as an adjuvant for a bird flu
      vaccine.&#160;&#160;The data indicate that a significantly lower dose bird flu
      vaccine may be possible based on CaP&#8217;s adjuvanting ability.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Also
      in
      July 2007, the Company announced positive pre-clinical results using CaP as
      a
      potential wrinkle filler in cosmetic medicine.&#160;&#160;BioSante previously
      signed an option and license agreement with Medical Aesthetics Technology
      Corporation for use of CaP in aesthetic medicine.</font></div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong><em>About
      BioSante Pharmaceuticals, Inc.</em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">BioSante
      is developing a pipeline of hormone therapy products to treat both men and
      women.&#160;&#160;These hormone therapy products are gel formulations for
      transdermal administration that deliver bio-identical estradiol and
      testosterone.&#160;&#160;BioSante's lead products include Elestrin&#8482; (estradiol
      gel) developed through FDA approval by BioSante indicated for the treatment
      of
      moderate-to-severe vasomotor symptoms associated with menopause, marketed in
      the
      U.S.&#160;by Bradley Pharmaceuticals, Inc., BioSante's licensee, and
      LibiGel<font style="DISPLAY: inline; FONT-SIZE: 10pt;"><sup>&#174;</sup></font>
      (transdermal testosterone gel) in Phase III clinical development by BioSante
      for
      the treatment of female sexual dysfunction (FSD).&#160;&#160;Also in development
      is Bio-T-Gel&#8482;, a testosterone gel for male hypogonadism, and an oral
      contraceptive in Phase II clinical development using BioSante patented
      technology.&#160;&#160;&#160;The current market in the U.S. for estrogen and
      testosterone products is approximately $2.5 billion and for oral contraceptives
      approximately $3.0 billion. The company also is developing its calcium phosphate
      nanotechnology (CaP) for novel vaccines, including hepatitis B, avian flu and
      biodefense vaccines for toxins such as anthrax, as well as a system for
      delivering drugs via alternative routes of administration and for aesthetic
      medicine.&#160;&#160;Additional information is available online at
      www.biosantepharma.com.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><em>This
      news release contains forward-looking statements within the meaning of the
      Private Securities Litigation Reform Act of 1995.&#160;&#160;The statements
      regarding BioSante contained in this news release that are not historical in
      nature, particularly those that utilize terminology such as &#8220;may,&#8221; &#8220;will,&#8221;
&#8220;should,&#8221; &#8220;would,&#8221; &#8220;likely,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;believes,&#8221;
&#8220;plans,&#8221; &#8220;hopes,&#8221; or comparable terminology, are forward-looking
      statements.&#160;&#160;Forward-looking statements are based on current
      expectations and assumptions, and entail various risks and uncertainties that
      could cause actual results to differ materially from those expressed in such
      forward-looking statements.&#160;&#160;Important factors known to BioSante that
      could cause actual results to differ materially from those expressed in such
      forward-looking statements include the difficulty of developing pharmaceutical
      products, obtaining regulatory and other approvals and achieving market
      acceptance, the success of clinical testing, and other factors identified and
      discussed from time to time in BioSante's filings with the Securities and
      Exchange Commission, including those factors discussed in BioSante's most recent
      annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, which
      discussions also are incorporated herein by reference.&#160;&#160;All
      forward-looking statements speak only as of the date of this news
      release.&#160;&#160;BioSante undertakes no obligation to update or revise any
      forward-looking statement, whether as a result of new information, future events
      or otherwise.</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"><strong>For
      more information, please contact:</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;">Phillip
      Donenberg, BioSante Pharmaceuticals, Inc.; (847) 478-0500;
      donenber@biosantepharma.com</font></div>
  </body>
</html>



</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>biosantelogo6.jpg
<DESCRIPTION>LOGO
<TEXT>
begin 644 biosantelogo6.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0`\17AI9@``24DJ``@````!`#$!`@`9
M````&@````````!%1$=!4FEZ97(@4V]F='=A<F4@4W5I=&4``/_;`$,``0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(
M`(\!4@,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)
M"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1
MH0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-4
M55976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::G
MJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U
M]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"
M`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2
M\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D
M969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2U
MMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,
M`P$``A$#$0`_`/YN/^'F'_!23_I()^VW_P")7_'O_P">-23_`/!3/_@I%#U_
MX*`?MQ'_`+NN^//_`,\;_.:^'Z6;_4GZ#^5?['U."N#(PG)<-<&74)-?['0>
MJ5UI[/OT_P`F8\\_YY?^!/\`S\E]Q_4I\(/V'O\`@Y?^.WPP^%_QC^'/[6G[
M2NI>`?BAX!\,_$[P=X@N/^"BVN!7TCQJL/C?0WUG1F^,NTK_`,(Y-&!Q\JDI
M@"-PG=_\.PO^#J4]?VF_VC#_`-Y,?&?_`,^FO[+_`/@DQ*;C_@F3_P`$^IG(
MN9S^Q7^S$'NL<MGX5^'P`#VY&3C/YBO</C!^V1^RM^SM>Z?I'[0'[2OP$^!>
ML:Y:MJ6CZ5\9?C1\-?AK?ZT`#\^BIXF\30>=#E0H,/F;BWR$KN8?YS9AXR<0
MTN(\URC`<&<$U%E%>M3AR\(TZKFJ=65-/2=ZCM%.;79W44M.J[27O3>BO[[T
MT5K]M_GIJ?PO?\.P/^#J0#_DYG]HO'M_P4]\8?R'QHJ"Z_X)G_\`!UQ8)F+X
M[_M8^(Q_TZ_\%+QIAQCH`_QJ0GZ9'89S7]J!_P""I?\`P39))_X>#?L2<_\`
M5V7P9_\`FEKN?AE^W-^Q=\<=6A\+_!C]KS]ECXH>(KBX-L=(^&'[0?P>\<^)
M`5SE4T+P]XC\522'@G;M&[*\+G!WK>,G'.'7-B.!>"U&S?\`R;6DD[6>K4=%
M;KJO0\SV.&TUG>^^JLW:V[?5OO>Q_F\_M'VW_!PS^QWI5YJO[3/Q:_X*>_#S
MP_IMLGV_QVO[4/QB\:_#C0ED8;!KGQ0\`?$*7X;1R2<A/,^*Y</UC=@RCX6_
MX>:?\%(_^D@7[;/_`(E?\>?_`)Y%?[!^J>'/#VLZ5J&F:IH^F:EI6L+MU33-
M2TJ/4=/O=X#8U/2IHS',#M'WTPV`7)``/^7O_P`%_?\`@F[X+_X)W_MBVUS\
M)M,TSP]\!OVB=(UKXD_#CP3->H-,\):QX>=X_BQX+T1@&_L'P_'+K?@H>#4*
MY!\=-"'0^$5*?L/@]XL\.<>XQ\-<2<"\&93G,J;G1JT\#1C2J<OV5!J34I<T
M6DG*+2=Y)I'0Z+5VJDFMK.5GWNO=2NW9=-EJ]#UO]E3]F_\`X.+OVVO@WX>^
M/?[/?[7/[3OC/X8^)M8U31K+Q#>?\%"O&/AS40_A";RW`TA?VB1&KSS',L>X
M2<^9+E3N/GW[;'A__@NY_P`$\="\$^*OVI_VR_VN/"6E_%#6M7\->"!HO[=?
MQ'\9;I-$SKKDMX>^-'A5=W]@<,S*2V,$JQX_IC_X-V_VL?V8OA;_`,$NOAGX
M1^*G[2?P%^''B33/B#\3C<^'?&WQ=^''@[Q(NG:SKDS:,=GCOX@M)N9&0#,K
M"0JJ1Q(VYI?S_P#^#KC]HG]GKX\?";]CS2_@]\=_@]\9!H'Q2\=:WK%O\*OB
M-X.^(S:)IG_"&`'6F'AWXAJ,X('S;5X'S9`5O)X<XNX@S3Q<7!^+X&X/62/$
MU:+DN$81M"G&HXRYW!J[C"#=5M1:DN57E`;H/E^.5N5+26MVXJ^U^KMJWH^Q
M_+W_`,/-/^"D?_20+]MG_P`2O^//_P`\BC_AYA_P4D_Z2"?MM_\`B5_Q[_\`
MGC5\/45_92X(X-=E_JUP:WI=?4Z%[Z7_`.7?=_U9A[2?\\__``)_Y^2^X^X?
M^'F'_!23_I()^VW_`.)7_'O_`.>-1_P\P_X*2?\`203]MO\`\2O^/?\`\\:O
MAZBA<$\%MI+AO@R[MI]4H=;?]._/^K,/:3_Y^2_\"?EY^GX>1]P?\/,_^"D?
M_20+]MG_`,2N^/'_`,\BE_X>:?\`!1L]?^"A/[;9_P"[KOCU_P#/&KX>_P"O
MC_@7^1^/3\>]?;/_``3B_8ZUK]OK]L[X$?LO6T]U;:/XP\1B]\>7=K:KIWV'
MX9:"!KOCM@R@`^(&\/Y*CL"HW,02W%GV2<`<.9)FV=8[AG@SDR2#G*^#H6:B
MD]5[/WM.B3TZW:!3FVK3EY>\_+S]/ZL?2O[/GQV_X+B?M=>()/#O[,_[2?\`
MP4M^->LF[VWEW\/OV@?CWXC\-:#CC9KWC=OB-X4^&>@`9(4,ZC`Y.>*_4_0O
M^";?_!U7J-NMY?\`QO\`VNO#AN>5TKQ5_P`%.F?4%P>TGASXSLBD8QC<#BO[
MT/@3^SO\*/V8_A?X7^#/P6\$Z'X#\`>%=+&CV6AV48<72*FQ]4U;5I(GDU[6
MY@0SR^(5>>=B091$BXJ?&7]I[]GK]G32K:_^-W[07P4^#UO<@`:G\7_BGX,^
M&RWI`Y^;Q&T:,,<#"@]17\`YWX\8W'YNX<(^&O!D,NYI1A3GPO2Q-1PC*RFX
MT^1\TG:\82FHMV]I)O05"U_?DU97=VO>LE;9Z>;U/X2?^'8?_!U'_P!',?M&
M_P#BSKQG[?\`59_?_.#1_P`.P_\`@ZC_`.CF/VC?_%G7C/\`^?/[_P`_0U_:
M;_P]-_X)M_\`20;]B+_Q+'X-?_-/1_P]&_X)N?\`20K]B#_Q+'X#?_-37(_%
MKCNW_)N."U?:_!+C_+M>=M-/2U]M\%0PU].:^G5OM_G^#/XLX_\`@F#_`,'4
M;20(?VF/VC!YXSE/^"G7C)VP`#\JI\9V=OHJD\8Q7XJ_%[]N+_@JK\$?BAXY
M^#GQ%_;G_;3T+QC\.O$NJ>#/&'A^S_;(^/.H`:KHA^<Z)K:_$5BQ)`.00>,D
M$G`_T]H_^"I'_!-3>V/^"@G[$9.#@?\`#4_P7SD^Q\4KGZ9R._I7^5A_P4!\
M2>'?B!^W-^UAXC\#ZKX<\:^%]?\`COXHUK1O$/A.\_X232]1TO(/]M:)K>@<
M%<@@]L@>F*_9_`+/<WX]XCK91Q;P/PA"E&%*<)KA*G1]Z4JETYN%G91BUHN6
M[YG*^FSHNR]YO7^;3[+3VW6O7RL:_P#P\T_X*1^7G_AX#^VUG_LZ_P"/6?3K
M_P`+&_R>>E'_``\P_P""DG_203]MO_Q*_P"/?_SQJ^'J*_K!\$<&)M?ZM<&Z
M.SO@Z"MMO^ZT_KLQ^TG_`#S_`/`G_GY+[C[A_P"'F'_!23_I()^VW_XE?\>_
M_GC4?\/,/^"DG_203]MO_P`2O^/?_P`\:OAZBDN">#'_`,TUP9_X1T/+_IWY
M_CY,/:3_`)Y_^!/_`#\E]Q]P_P##S#_@I)_TD$_;;_\`$K_CW_\`/&H_X>8?
M\%)/^D@G[;?_`(E?\>__`)XU?#U%'^I'!G_1-<&?^$=#R_Z=^?X^3#VD_P">
M?_@3_P`_)?<?</\`P\P_X*2?])!/VV__`!*_X]__`#QJ/^'F'_!23_I()^VW
M_P")7_'O_P">-7P]13_U(X,T_P",:X,UV_V.AKM_T[\_ZLP]I/\`GG_X$_\`
M/R7W'W#_`,/,/^"DG_203]MO_P`2O^/?_P`\:C_AY;_P4D_Z2!?MQ_\`B5OQ
M[_\`GBU\/44O]2>"U9OAK@RW_8'0\O\`IWKOM\NC#GG_`#R_\"?^?DON/N+_
M`(>;?\%'O-43_P#!03]MP6X'^E?\98?'H!>@./\`BX_<=<<8]:_;SX/_`+"7
M_!S#^T!\*/AW\;OAE^U9^TGK'P\^+_@7PS\2_!.JC_@H9XOTQ[SPWXXT-=?T
M-64?&@,K"/6HL@Y.%3L%`_EAK_8&_P""3<,'_#L'_@GV?)X_X8U_9R^H'_"K
MO#O'Y\YQT/7M7\Z?2'SW!>&V%R7_`%:X>X+MG4VIN?"M"3C'DD_=E>#7O**;
M?-HV[)JYRY;*7O7E+;^9[\T=_E?^M#_.*_:\^,?_``65_8.^+MS\#?VE?VX/
MVOO"_P`3QX2T[Q/;6WAS]NCXC^)=*73M9UK^UP2Z^)<^9'H"-$=V"A15^8$Q
MK\H3_P#!3#_@I*PP?^"@?[;97MG]J_X]$#&#T/Q&^@K]:_\`@ZIS#_P52O\`
MRL6Y_P"%$?!W)&.<MXAQZ]OSXZY%?S95^L>&62\,\7<`<*<28_AS@UYQ6IPE
M47U*A3C)RC&4E*GRR2LV[1<I..SE)IR?6Y34G[\W9M+WGLGIU_%)'W#_`,/,
M/^"DG_203]MO_P`2O^/?_P`\:C_AYA_P4D_Z2"?MM_\`B5_Q[_\`GC5\/45]
MG_J3P9UX:X,3Z_[)0WTOK[/S_'R8O:3_`)Y_^!/_`#\E]Q]P_P##S#_@I)_T
MD$_;;_\`$K_CW_\`/&H_X>8?\%)/^D@G[;?_`(E?\>__`)XU?#U%'^I/!?\`
MT3?!G_A)0\O^G?G^/DP]I/\`GE_X$_+S]/P\C[A_X>8?\%)/^D@G[;?_`(E?
M\>__`)XU)+_P4S_X*1"/(_X*`_MQ*1Z?M6_'@'VY'Q&_7C\:^'Z6;_4GZ#^5
M98W@G@V-&K*/#7!J:I3::PE'I#1K]W;3=:]O,.>?\\O_``)_YG^S/^R!<ZSX
MK_9+_9=\4>(_$WB;6_$/B3]G7X)Z_KNLZOK']HZMJ^LZQ\-/#.HZIJ>IZAY9
M^W:A?WUS/=WMYG_2KF66?^.BL[]BO_DS?]DO_LV;X#_^JL\*T5_DSC546,Q:
MC444L372BJ<;12JS22\DM$>HDK+T7Z?Y(_QJ*6;_`%)^@_E24LW^I/T'\J_V
M,JQBZ5566M.?1?RL\D_V`O\`@DX1_P`.PO\`@GP1V_8I_9A7\3\&?#0_^O7\
M@W_!XQ@?M+?L5R*")HO@M\8KE?H/%T)'/'3=CC`X]<U_7M_P25'_`!K%_P""
M??O^Q9^S!_ZJWPZ/Z5\__P#!1C_@B]^RW_P4\\9?"SQ[^T-XI^-?AC5OA-X?
MU30O"=K\'_%_@W2UDTK77620ZROCWX<>+S(=RC!^3+@Y)(:O\I.#.+,JX#\7
M,RXDSJ+J93E&.QDYP48RE4O5Q$$N63479R35[*Z2=D^9=3[+=J/W>YVOJM7:
MVOY?Y0'V.#_GC;?DW^-7[/4M5T&_M]<TJ^U+1-8T&\^VZ/JVDWG]FZG8:ITQ
MH>N'CM[?C7^CJ/\`@T>_X)@'I\1OVQ/Q^+OPT'\_@N*[CX4_\&M?_!+?X3^/
M]/\`&]Q;?'SXM+H*/=VWPX^*OQ%T'5/!&YUQ'+JFC>!/AWX3\1:ZT3MG;<>)
MIT=L+L9<[OZSS[Z5OA=C\OJ1PF$XDBYTY)<W#V%:NX\MHR55^5F]+=3F6&2L
M[PW7Z?W?/7Y]C]E?V)/&'COXD_L8?LI?$3XDR7EU\1_'?[,WP(\;>/9[Q#I]
M]KGCWQ'\'/!&N>)9'1=O]B-+XAEG,B$D>9G/+,3_`",?\'C&IZ8TG[`GA9H;
M:Z\7B_\`CSK-B1<-&=/\+)_PK]&+AF)^:4:,Z.`%:/0_$6W<#O;^Q7X[_'_X
M,?LC?!_7OBO\9_&6A_#+X7>!+"/^UM?U;_5Z<22-%TI=)T!&+YC.$`7Y@!T6
M0NO^5]_P5J_X*%>(O^"E'[6VN_'8:;K&B?#'PSX:U3P!\"_"=TA74K#X9.[-
MHNN,N"I\1>+VUO7)6"EA_P`20#)8,!_/WT=>'<9Q!XHY=Q%@X?\`"1D\JM:<
MK-)N;]Q-/=M/;:*7+:*=.)S9BVN6U_B2VOHG'LG975METT;/V5_X)0?\&Z/[
M._\`P4-_8I\$?M6>/?C=\8/!7C;Q?XM\=6=YI?A;P]X.OM*QH6N2Z'@:-K\3
MCJK,QW<`_-@!,_*?_!<C_@BW\(/^"5/@O]G_`,6?"3XF_$3X@3_&3Q+X[\&:
MI;>--*T:Q%B%\'!D=3X?4`$C(*[67D_>X)_K*_X-BX(1_P`$E/@U$(;;!^*'
MQ@`XXR-<DR1@9RVY0<9X"FOS9_X/&H8H?@]^P_,T6YA\8?'H)]/^*+SCMSC!
MXR.?K7W/#?B9QOB?I!2X;GQ'-Y++BBOD+R+V5"-*G352484Y34%4;C!QFI*\
MFU>51Q;B=*2<$[+:-UK=NR;;5N^[;MTML?P9S]OP_K7](G_!.?\`X-N/VGOV
MTO#>@?&;XR^(K?\`9@^"&N6NEWGA.ZU_2(]3^)OQ%TMD,BZWI'@@LA\/[AM4
M#Q6"Q,B,4\81$LO*?\&ZW_!.CPO^VM^VC/X]^,/A5-5^"'[,5EI7C[Q)X=U^
MP34M+\=>/-<Y^%.C:WHI0HN@A=7_`.$I'AI3B0Z`$>0B1A7^DU\6_B?\//@-
M\-_%_P`6OB)K6F>$O`'@+P[J?B7Q)J]WA4T_2M"7<7`SG')``!);`.`2P^\\
M=O'7-^%\X_U"X"C'^V832J\2*$JM1RDHVH4H))\\[QNVI6C9*-Y\].5AXO5V
M5]NVKW=X+L_SOT?\U>A?\&C/_!-K2=-1O$'Q1_;(\5ZH03>:HWQ$^&]@SGMM
MTA?@RB+_`-^W)SQMQ7S!^T5_P:)?"'4-*U>]_95_:4^*/A/Q``HTSPM^T!:^
M#?&OA;Q065G9_P"WO`WAN#Q-H4*;<%X_"$DF6&Z%`"5^9OCK_P`'=/QRU3XB
M:@O[,/[-/PW@^'.AZM]CTF\^,3>,=>^)7BS3%`#:RNB^`77PUX<#;=X!EE?Y
MMH9B<#]Q?^"/?_!=+P!_P4QU/5_@YX_\$M\#OVC_``]9)XR/A*UUAO$O@GXD
M^%VV`ZUX*UZ3#-Y9.)O#+;F78[!G!)/XOCZ?TD^$\LCQWFV;8W^R9R4JEZD*
MLHWDFG*C/GA"$G9+V4%RIZJ$.:2RY\&VHWBVDG;5/INU9WT7Q-W:=KZ'^=_^
MU[^QQ^T!^PG\6;[X(_M%?#2]\&>+COO/#A4-JOA?Q;IL<A1O&'PPUT%?[>\/
MJR%7\,>)_G7E6_>[@G[O?\&FOAC0M<_X*-?$?6K\PW$_A;]G/QMJ.C_:+38U
MBVL:_P"'=&1<Y`VOX>UG6T<$@,I*]#7]A/\`P6+_`."=_@K_`(*)_L:^/_AI
M>:%;_P#"U/!VD>*/'WP4\6W5HO\`:6@^.M$0$:4&#J?+\79:%UP68$,,(K%O
MX)?^""W[67AS]C/_`(*??#'5?BE/;^%/!_Q.MO$WP7\=G5+/^SAX4U37"=#T
M+^W"X4C_`(1?Q&O_`!6NX*0I)X*Y'[+A/%'%^+W@9Q_@<9%3S[)*-Y1IK6K[
MGV(WYFIM-13DVFG'FER\ST6'BI1[-IJ]NZ=OA7\R^79(_P!2SQSJESH/A#Q?
MKFEP+<ZCHGAGQ'K&EVS<!K_2='F$*#)P=TH"8ZD.1RQ&/\7SXX_%KXC_`!^^
M-OQ'^,WQ3US4_$?Q&\4>,/%&MWEQX@)U/4M"(UG7R-%&M:^2/^$?\*#"C``Q
M@'&":_VF)O+O8N2+BWN+4@VUMB_T^]T\@`$?*!N97(!4C<"`-P;-?S8?M)_\
M&O\`_P`$^_VA/BMXO^)VA>(OC1\%-?\`&6K:GK?C#PM\/-:\'WW@F^DULX;^
MP]`U[PS(OA\9`(99#S\N"`&/\Y>!'B+PGX:9QFCXHI.<<YC&,9JGSR@XMMKE
MLY[VLHPD^;65F=;U2\M$GMY6>MNM[]-MK'^:;Y-O_P`\(/\`/X4OE67_`#[V
M_P"G^-?Z&/\`Q!]?L9_]'+_M+_\`@/\`#?\`^9:HM1_X,^OV-I[6<1?M/_M'
M6K$9-T+7X:M^6?#`/<<\?RK^NU]*/PHT3QO$:6FGU5\MO=7_`#ZV_P`Q6\E^
M'E_P/N\M/\]#[#;_`//E;?\`@'5GR8/]'@X^S?\`+G:?4?S]_?O7]<'[8?\`
MP:A?'GX-^#]?\>?LF?&+1_VE&TVR2\'P_P#&FC:1\*_B*=.\LNXT+Q`OB/\`
MX5KKFP#:6NH;8,[!8PQ.T?R4:_H6M^%==U_PYXCTG4]+\0Z!JYLM9\/ZM:?V
M=J6AZIDG7-&UL8X_NYR>QP"#G]2X(\1^#N/FWP;F48U+/FBX*%2,G&ZO!\M1
M-W6ZZW2ZG.TU:Z>OIIIZ_+2^K/ZJ?^"._P#P;\_`O_@I3^QAH_[2'Q$^-_Q>
M^''C"Z^(OCKP#>Z5X6T+1;[3`/`^MX48UZ.3.3@=L,0I`;(K]6?^(/+]DS_H
MZ[]H''_8`\'_`,O+_K7\\G_!.#_@X`^._P#P35_9Q7]G3X9?`GX0_$GP_;>.
M?'7C+_A(/%GC#6=,)U/72-<(51UVL"JL&!.WC:Q(K[^/_!X)^UZ3G_AD3]G'
M[1_S\_\`">>,1SCT"_KT]LU_-/%V1_2@Q'$N=?ZOYO4>3NM)T8P^J1BJ3MRV
M52BIJSNFFYS;UYK-*-)QTNE>R;=Y+7KIKYVV73<_0Z7_`(,]?V3(8I_^,KOV
MC/\`CTQD>'_!WOZQ\GIE>.,\G@5\0_M)_P#!HK\4_"^@:KK'[)O[3NB_%G5[
M:RDU"W\`_&'P/J7PY35XD^[I.D^-M"E\5:!_;\I!1#'!X356!\PQKS5?0O\`
M@\&_:6TS4[`^+_V,/A#JFD[A;&UTGXE>,_#6I7XQMSHIU[X>,#_"NQE*@8'4
M`5_7G_P3Z_;F^%O_``4@_9M\)?M&_#32M8T33M3O-2T35_"WB.UQJ?@;Q7H9
M\O7-$D*KMUX[O+&]0R[3\J`*!7YCGG%/TB_#9PS?BS.*KRNZWIT*M.4E9N%6
M,:<)\DDFKQE2U?*IJ<HWW3B^B?E=I]-K^JZ/[C_(Q^(_PT\?_!OXB^*?A;\4
M_!VM>"O'_@O5]2T;Q+X4U?2%'B6PU/0\\9)&=`)&1XF4%F`9E!"FOT[_`.",
MG_!.;P'_`,%,?VHO$7P"^)/CWQI\.?#6E?![5?B;8Z_X+M='OM1U`Z%K6@:"
M`SZ\CE0#KG)",0.BDU^]O_!W?^S+X<TS5?V8/VN?#GAQ;;Q3XD7Q-\)?B1?1
MX5-0TS0SH6N>!O[;C#$ZX%?6->4(6;:-HW,P;;\1_P#!I5_RDF^),_D?:+C_
M`(9D\=Y/I_Q6O@'I]<GI_P#6K^DLQ\4<TXD^C]/CO)I_V+G,8U(2E32YH3IW
MIU'#VD;.49QER<\>5V6DHO7F6&2ET>JLK6[;M+KOI9JY^Q'_`!!V_LA_]':_
MM'_^"KX:?_,W2'_@SN_9%_?X_:T_://7_F$_#08]/^99/X8SSVK^DG]MG]I&
M;]D;]E;XX_M$V/A7_A/;_P""G@4^,;+PK<:N/#W]O-_:O]D#23K6UHX6W%CF
M12&94)W&1!7\@L'_``>6^.!G_C73X4()Y_XRJUD<Y]1^S>/0`_CU/-?RIPKQ
M)](7C?"YEB^&LWXESJ.2MJI.$J/+!VC*[4H2<D[]%=1::Z-=*LM[>7WI6W7]
M.U[V.A^)_P#P9WZ;'HEWJOP4_;2N5UN")'MO#?QI^$3/X81FR2AUSP-\0H)T
M(`^]+;>+,<(5#_)7\G?[9W[$?Q[_`&#/BMJ'P;_:8\`S^"O&%T=5UG1O$%I>
M_P!H^"/'7A@,"=;^%^LZ$O/1XV3Q7AD92)54@!_]+7_@D5_P5X^'/_!5KP/\
M0];\-?#_`%GX3>-OA+J'ANR\>>"-3\1:+XATTMXATAY-$UK0M:T/8KZ#<2Z)
MKB('6-O,T4LWS%A7P'_P=2_`+0OB!_P3ZT?XZ6.CV]OXZ_9V^+GA>_T?4F9=
M-_XI;QLXT#Q!I*C:&.?,T!7RQ1,>(PB)EMWVGA_XT^(W#_'&5<(\>RJ9PZDX
M4W3KPIJI2J57%02E245*+<XW5YO57E'EG!\SPT6KJW?2]FEW3CIU\]DTU:_X
MH_\`!(+_`(-\?@'_`,%&?V+_``_^U!\3/C=\6?`/B#Q1XZ\>>&;SP]X3\/:,
M-,L6\"^,]?T(``@_,0,GD`$G@#@?W>?LN?`S2?V:_P!G#X(_L\:5KNL:WH7P
M.^$7@/X1Z3XAU0BRU/6M+\#>#=`\/Q:RX`1HWEBT97Q@;07^9E`9O\TS_@G_
M`/\`!>_]L+_@GQ^SUHW[-WP7^&/P#\1_#_0/$?BCQ./$'CCP]XTU+4CJ>O:R
M=>UW=K7A[XD*C\$XRI`Z@Y&:_P!'C]A_XW^)/VC_`-D#]F#]HOQCHNF:+XF^
M-7P%^%OQE\16&CW>_P`.V'B;Q[X+AU[6=)T9G9F^1]7EP<$,"6)+(37QOT@\
M!XC87.,PQG%]1O):U67^J\7RVA"47.,8N,8M<JBOB<W?F7,U9J<NLT]$K1=[
MO?5>;V[+?6W2WY=?\%(/^#?SX"_\%*?VB+C]I+XB_&_XJ_#GQ'=_#KPWX*71
M_">E:-?:58+H32-'K`.OH_S[`H9<``AB"0!G^5#_`(+;?\$2_@K_`,$N/A)\
M$?'WPK^+WQ/^)6O?%GXH>(O`FJVGCA_!NGI:1Z3HCZZIT3R_#B,"#$P.UB&^
M5@V,@?MO_P`%H/\`@O7^UK_P3W_;0U?]G?X(?##X&^,?"(^$7@7Q3::I\1/#
MWQ(U/55U;QO_`,)%JY!_X1OQ/X6C*D:'D(KMMZL%E4A?Y=/^"DG_``6F_:2_
MX*;_``W\(_#S]HOP!\#/">A?#'QSJ7Q`\.7?P]\.>,O#>IWRZSHSZ$!M\0?$
M?Q:O1V)(&2",G"[1^F^"N3>.&$PW"><K-)+PSC:<X)T>5TE1G9)<CJJU1P;]
MZ%FK<SBG&77I9I[VMI=.]UOKH[7MV[7LU\%?LP?LN?'?]L[XLZ#\$?V;OAUJ
M/Q(\?^)C]MO-+TEETX:#I8+#^V_&WC?Q`?\`A&?`2G;]X#9GCDE0?ZR/@I_P
M:#^,-7TFWU3]HC]K#0?".M:@--;5?!/P:^%^J^-$T;8%<,OQ2\??$7PRQUP.
MPCE;PWX+4J1Q'(C*#^ZW_!`W_@G]H7[$?[#?PVUG7M$:T^/?[17A_2_C'\9-
M>NXW;Q+:'7=#C?P/\.3K2>6PA\&_#V308I/#A<1?\)F?%'C`-YLZHW,?\%??
M^"YW@+_@F-XI\(_!SP[\*=1^.'Q_\:^#Q\2(_!\^L1^'/#/@?PG(-9T8ZSXW
MUPI(8DED@DA\K))2+S=ZX1X_)XS\;/$;C#C:IPEX;2=.E"K.E3G3A3=2LZ4_
M93JMU8RI1HSDGR.UYQY9J?OQB#7*K3L[V3[:I632UOJDUW?*EIK\#6O_``9]
M?LEK#_IW[6?[1U_==?M)\*>"-/8?]^_#D@]._P"><UROQ!_X-&?V5/"O@7QK
MXJL?VI/CO<WOACPCXF\36MOJFA^#GTW^TM&T>36T;65$'SEF5<@L@`9R&8(0
MWQ#/_P`'AW[4MY)<>1^QO\%M/@M[K#?:_'OQ*U#;V`!3X=9!!Y!PK#GCFL'Q
M3_P=S?M(>*O"_BGPU>_LB_"'3;+Q!X:\2Z'?7=I\0?&IU&Q76=(DT5=8VGX<
M;``TK?=0%EPI.U%`[,)PY]*+ZY1>,S:M;G@YIRPB;@I1YE*V'DK-)W5.S:O9
M]3A3P;?W;\[UND]VNMKWOLK7T/Y((A!J/V>^\_\`T>ZL]5O?^/0:<"0->_L/
MD<$?\23C'3.#R#3)O]5/]/ZFKD5G<:;`+"XM_LIM;0Z03]I_M$8T;6-=T+7!
MP`,?\3LD``*!RN0352:']U^'\OZ?J>M?W;AU)</OZ]9U%0:;T?O<CN[[ZR-(
M[+TZ;6Z?>C_9*_8M)_X8Z_9-Y/\`R;1\".Y_Z);X5HI/V+?^3.OV3?\`LVCX
M$?\`JK?"M%?X]9A;Z_CK;?7,3;T]M,]^"7+'3[,?R7^2^X_QMJ6;_4GZ#^5)
M2S?ZD_0?RK_8BMK1J_\`7NI_Z2SP3_8`_P""2K#_`(=C?\$_,=OV*?V7A^(^
M%WAX_P!*^#O^"O'_``6Y\-_\$I/B1\&OAUK7P+\3?&F3XQ>$?$_C2UN](\6:
M+X:_L4>"?%:KK:2^=&^_*N)`0$R8UC8G;+&_WA_P26&/^"8G_!/O'?\`8K_9
M@)_'X6>'O\_C7\B?_!WOH&LZO^TY^QS/HVAZUK5H/@5\8+2^O=(TC6=0CLW'
MB^%6?5DT+092D>_($9.1M9B&7,K_`.4W`O#N0<4^,U7)^)K1R:KCL;[5N3BK
M*K7DO>O%Q?-&*YKNR?J=,MKWLTHO7;[._K=K].C^FS_P>1^#3_S8_P")O_#X
M>#A_+P[7H7PL_P"#OC]GOQ7XOL-"^+7[*GQ3\!^#]37%QXL\+^+?#_Q%72AC
M;MUG0H(H#M/!(RS`#J`":_@F_P"$;\2?]`/Q)_X36L5Z7X6^`OQI^+'C2P\`
M>`/AE\1_''CCQ?K)T72=(\/^$?&&I:CK^U]N%T77?#O_`!(EZ'=XI8$C<RX4
M;Z_L?/O`#P,P63U*D*D%4]G-IKB-7T5UIS>BNTNUSE]OY?A_]M_5T?[)MPOP
ML^._PKA?4;#PW\5OA7\2O#&E:A;6.K:;I/B/POXK\->,D#:*S:1KBMX>N(WC
ME0JLD+94*7B65PM?YH__``7V_P""9W@C_@G/^U5H-U\)[%=-^`/[1'AW4_'W
M@30+J^U74-0^'?BKP.,_%3P='JS/)((<^-O!9\%LV\!O'BQDK_PBL<LG^BQ^
MPY\(O$_[/O['7[+'P-\:O:0^,OA=^SU\'/!/C*.SO/[2TW_A*?!'@C0=#\:M
MH[`%EC/B))0IVE7+@H"0*_E4_P"#QC4]"M_`G["NB7I-MXIO/&'QXUNP*G'_
M`!3'@G0O#H<-WVMX@UWP4<@Y)89XR*_E/P&SK-,H\6LNR;`5)/)\XG5H-)J4
M:BIJ3BY**Y>91CK-)<KYE:VBZ96:>G;Y7:6^]G?SMHUJC]3O^#8C]U_P22^#
M2\_\E$^+Q'I_R'9L\9[@>O8=J_-K_@\B_P"20_L-?]EB\=?^H2I_G7Z2?\&Q
MW_*)3X.?]E$^+_\`Z?9J_-O_`(/(O^20_L-_]EB\=?\`J$K7M<))_P#$SJMO
M_KCBM?[WM*UOG^)B^O\`A37S4/TL>G_\&AG@+0="_8U_:.^)$('_``D/C'XZ
MZ?H>KW?MX'\&QG1..X)\;:UG\N]?2_\`P=+?$+Q#X)_X)::QX7T>>2QL/BG\
M;/AKX!\27=KY:2+X8DUI]?UA&V*RG_A(_P"PTB8$%G362K.68R#\]_\`@SX^
M.^B7?@?]KO\`9NU"_MQK^E>,/"_Q:\-Z1E?[2U#2F3^P/&^MMGJ!XB_L%54'
M@L`1Q@?M=_P7G_9"\6?MB_\`!-;XS^`OA_HJZW\2/`]WI?QH\&:2-I;7M0\!
MZTNN:UX.BVLN[7O%7AQM;\-I\VW?+ABH;;7!Q7*.5_2*JXO.%RP7%E*[E\+C
M*%)0FG=6C&5HWT5X2LFTB>E]7=:6N[:[+;Y>J[G^5+Y'O^O_`-:OT6_X)$>/
M]:^&O_!2K]B+Q!HM[NEU?]H'P)X6OEM[/^SPVD:_K)775;H&!!VD$<@D?3\\
M]2M[BQN9[*YM[FVN+>[^QZO9WED=-U+0_$W(.CZWHFO'G#`J1TW!@3D$5^ZO
M_!O1^QIXR_:?_P""B7P8\?V.A70^&'[.GCD?%CQWXL%I_P`4U_:F@1C7-"\&
M<G&3XC&AGKQ^5?W;XE9IDF'\/>*L3FN94ZL949*%)3C:;=-)0BM5[WPW2WTU
MU$J$;IJUN_3==.77Y=FC_4L\J%%`QE60Y[]B/88X!S]#VX_QM/V_/#</@K]O
M#]KGPKI7^CZ?I/[3?Q/LS[#7?&FO>.QGVY`QVR`*_P!A[Q9XGTCP)X5U_P`7
M>(+VUT[1/#.CZGK>K7EU<_8H[+3='TII9"23C`V[@Q(4%@<$[!7^,7^TA\0A
M\?OVE?CC\5;$?VE!\6OC#\3OB#X/M+RTUC^TM0TO7?&;?\(-HN/#XR?$7_".
M[>0"!T;DK7\?_1&RW%3XAXKQ<TI9/*E2C5F[>SFI.>E[N-]9-]$JB:O=F&8W
M2A;;FV\N:.Z7RU2Z;:6/W5_87_X.3_VY/V1O"FA?#7XF:/X:_:G^&/A&S%GI
M%G\2]8/@KXEZ!I:_=T4?%+0BW_"0E1\H;Q=X/9BJJ&8X&/V"TG_@\7^$<MM`
M/$7[%'Q0AGN20+;1_'?@[4@1ZC<`V#C.&45_"\=!\8_]"=XD_P!%_P"H/K/^
M@>O7Z<4'0?&/FG[1X.\2=_\`F6]9]L_Y^O/>OZ0SGP&\%,\QKQN)RVC%R<IR
MY.(H03G.2G*7+_,YN4I-6;DW?75;INR=W\*6^^B_R/[QO^(Q;]GG_HS#XW?^
M%Y\,O_FBKV7]GS_@[#_8S^*?CG0_`_Q-^"/QL^!NG^)=6&AV?Q`O;[P=XT\"
MV.IZYJ^T'7M8\.^(4\0:"6W;P!$R*5!V*%CV_P">I_PC7C#_`*$_Q)_X3>M?
MXU[U\`OV1OVA/VH/B7X=^$WP<^#WC[Q;XQUW6!9-:-X.\8E=`TU3C^V=;UP^
M'?"BZ$GA0;6RWB\`DL-N!EOC\_\``#P6P>2U,;"O&,XPFXM<2P;C*,>S;5E;
M=KENM;[,6(3:6CNTK::W^?\`7X/_`&6-/U6QO+>WU2RO+6>VU2STV^MKJ'`6
M^CUEL:,QSD%2I&W)Y#!B``<?YEG_``<Y_LWZ)\!_^"FVK>-_"UAIOAS0/VBO
MASX9^)MYIAM"=,;QWH1.@^-]:;`"*2%T5R%4#<SCH!C_`$E/A3X3F^'GPM^%
MW@C4\7^J>#?AUX&\'7UWC`U#4]%T70]#=\GCYI-%\PMC&,]^#_`#_P`'>'B7
M2]:_;6^"/A#2KVW76/`?[.6L+XDM#S_Q*M;UPZVI&/[ZKN'?!QC@FOY@^CUC
M,7D_B>W@')TXT\0X)2]R4(.%IO92M>*BTM54<M-GTXG9WLNNW7WE;\=GU2ZG
MD?\`P2+_`.#?'Q?^W]X(L?VA?CAXYU'X&?LY:YJVI'P)I'A^U/\`PLSXE:7H
MI*:OK.B_V\K>'/#_`(>E8>5#XGCBD=WPJ*>0/Z<_!_\`P:V?\$I?#]A!!JOA
M#XT_$`@9%UXM^*37Y.>OS>'O#OA/@^H7@Y!SV_9[]D/X=^$_AS^RW^S_`.!_
M#EE:Z;I'A_X*_#+1;-+2T%AIY5/!VA:QN`7.%+#)89VC*L`V0O\`(]_P7L_X
M+;_MQ_LG_MJ^(?V3_P!F7Q5H?PF\+>!?`G@/Q+?>*?\`A$='\3>,_%.I^-M&
M_MH1Q)KX\N-(PNS"1J6*EG!<L3[=7C7Q:\6^/:F2\/<6SR-.=5TXJI+#4X0A
M.,5S.#O)R3@_?<TFVX*"]UM=$DNBV3?W/MY6]7HS]@H?^#9+_@D/:2"X3X$>
M-;<V_(+?%WQL%Z9&3_PD1QGMNP>GKBOTX_8S_85_9S_8%^&>H?"/]F?PQK7A
M/P-JFL:GXGN[37O$FM>(F_M76FQ(0VO2.=I(4;/E*\JY.[`_S9/^(B?_`(+#
MR_N?^&O=1STX^%7P;!],8_X1K'MU/;UK^SG_`(-U?VV/VC_VZ?V3?B;\5?VD
M/B5<?$KQOH/Q@U7P7I>K7.BZ+X;L&TI-#T)HU71M`T"(+F1B?F\Q3N884,SJ
MO%GP[\8>%N'OKG'/%?\`;^4MTXJ"XBE6UE.,8M4[W24FI-I)02NW9-(_KI_P
M+[;?JSY=_P"#N>'_`(P5^!_[CC_AH_2O_3-X@^O;/IQV%?B/_P`&E?\`RDB^
M(_\`V;)X[_\`4V\`U^WW_!W)_P`F+_`W_LXU?_3%K]?B%_P:3?\`*2?XC_\`
M9LOCG_U-?`-?<\%/_CE[BSJHRK6U;M:<MF^^OXF'VDNONZ==D?VB_P#!:&'_
M`(U8_MN8@MN?@MJHXXR?[6T,X/M@9'N!SV/^1E#^Z]^OZ_E_2O\`75_X+0_\
MHM_VW/\`LBVJ?^G;0Z_R*J^M^APW_8'%^K_C)/5_\^,/O^/X^9RYAO'_`!/_
M`-*1_9A_P9R&:;XS?MR&?[W_``J_]G?/&?\`F</BYC)^N>_MBOZ`_P#@Y%MX
M!_P1Y_:I;R(/]&N/A==9(`^Q%?BCX$.<`#GG/8$$`#T_G[_X,W_^2R_MQ_\`
M9+OV=_\`U,/B[7]`_P#P<D?\H=_VJ?\`KZ^%_P#ZNCX?U^8^)B2^DGEJ2M_M
MG#=^G_+O"MW\M7=??<Z4O<ANW9^?6_X79_E@S0^D'_+G_P#KP/R!'Z=Z_P!@
MG_@DR-W_``3"_P"">$C$-*?V,_V<E:X(Y(/PM\#9!/&0P`ZG^$XK_'^_^0_^
M7K_V7_/K7^OW_P`$CSYO_!+/_@GG/B`D_L5_LY#ID#'PK\.'\L=C_%NS7Z-]
M,K3A[@%O:_O-_P"!/7\=_,Y<M6LKK97VU^./Z'\)7_!UC%`?^"IVH0#/_)"/
M@Z/KAO$`'M_7UZ<_SHZ#H,&O:UX?\.S_`.C6^NZSI?AG_N%Z[K6?7KGZ_P`Z
M_IK_`.#LCX<:SX8_X*+^"OB#J=M?P^&?B'^SGX5O/#NO?9M^G7^J^#/&/B'P
M9KO@N-U0(VNQH\?B<$E3L\1Q%58%F7^7T2WVFD:K8DVVH:6?[:M#CIJG_,".
M,C)QT`QD]Z_7?!_&X/%^#V6Y?A9J4UPK.$H*2;=6,.6:44W[RFI+39JUWJ=3
MW:[/_@_DT?[=NBZ?;Z?HNG:78P?9K"ULA9V?.2-W`]^W''7L<5^2O[8O_!$3
M]@O]NKXTZA\=_P!H'P3\1O$?Q`\3>'-+\+WMYI/Q%UKP[IEEI>@9&B;=#1DP
M^X'/7#`Y4'BOT4_9[^+7AGXZ_`KX/_&_P3JMM=^$OB9\-_`7C71]3'*WND^(
M/"*Z]$Q!P`0=6#<<`H^,\5_)I_P7M_X*O_\`!2C_`()S_M?:3X4^"^M>$O#G
M[/7CGX0^&O&/PVO_`!!X!'B+2[[Q/)K1T/Q#HAUPA0?$7AB31-7\42>&ED5!
MX.USPV61F`5/\]>"<FXLS7CJ63\*9O\`V)GG-.*J3J.A-RC/WUSI^TC+W;S2
M5TXN\;I(Z+];::/17T[V>^CT]=#]'(/^#7/_`()/PQ?9XOAU\5Q">Q^+NL`\
M^QT,Y_!OK[^>_%3_`(-D/^"5GAGX7_$;Q%HWPZ^)\.M:%X%\;ZSH\]Q\4M7#
M+JFC:/K>LZ.YSH;?*DF2Y'*HNQ1*R@M_+#_Q%'?\%;?^BJ?!3_PS^B__`#1U
MA^(_^#F__@JEXG\/:[X=USXD_!JYTC6](U+1=5MK7X4Z/I^IW>F:WHCKK10?
M\)&2I"NRKL&0&8#AB*_I7"^&/TA5C*3Q7'\;1G!SYN*ZS]U6<K1][F;5_==E
M)-IZZ'/>-TVEI_=CO:*Z^G2S/P.:0B%;F":XMK;5+K^V+)@&`LM-QKVAL,G`
M,GBC^R`&`P!A>H^]%-_JI_I_4U=ABGM_M%B`$.G77]BW=L"VG&^U,:P^MNI&
M>/\`A&&X.X#';"$YIC_4W'^>YK^XZ&&:R"<9RYIQH-2=[\TE!IRZK?KNW>^E
MCDC?KJ^_??HFUIL_-;)6/]E']BW_`),Z_9-_[-H^!'_JK?"M%'[%O_)G7[)O
M_9M'P(_]5;X5HK_'G,%;'XY=L9B5_P"5IGU$/@C_`(8_DC_&VI9O]2?H/Y4E
M+-_J3]!_*O\`8FI%RA.*T<H2BGYM-+\SP=C_`%__`/@DK@?\$QO^"?84C)_8
MK_9?S_X:WPZ>?3D@U]RZSX/\)>(;BWGU_P`)>'M;N;8&"SN=8T'1]4-F,<KN
MF$K*AXPJ;`I/&TDY_P`UCX`?M;_MGZ!\!/@SHO@;]L+]H[PEX9T[X<>`K3PC
MX4\/>(]%'AO0],`"C1F(\-?\)0?#X557).0J@#@8KUK_`(;5_;L_Z/E_:8_\
M+KP7_P#.VK_-S._`+B>/$><XVGFU&'M,17J1E'VB7LZM:52.D7%\[C.TFFU=
MRLFK7YGG6";TNG9;)7325^GEV/\`1#_X5SX$_P"A%\&G_N7=%]NG_$F'J.O/
M-:.C^$_#/AU9Y/#GA_1=!:_;[5>-H6EZ1IIOGV@@R!$4,<$')P.<[@3FO\ZO
M_AMC]O/_`*/E_:B_\+OP9_\`.XK.N_VR_P!M^\B^PS?MO_M:7$'_`#]CXCZ-
MIO;V^&XS_P#6QZ"N9>`'%^+3A/B>C[.7*I1DZDE;1ZQE=2L[63:V7JDLZP6E
MKWT[>GXG^@G\6_C9\)?V??`^M?$3XQ>/_"7PV\&:%9-K&L>*_&FM:5IFG6"E
M>#O4QG67!+?=)88!5@V=O^7K_P`%N_\`@I@O_!2_]K5?&'@IM2@_9Z^$'AW5
M?!GP4:]9?[2\4Z<9=_CKXE:SH_EP+X?'Q2&BK$GAHHK^3X"\+M*=[2-7/_M%
M?!GXQ?'B74-<\5?M#?%KXH^(+7_CSM/C'XPUGQ+IGUT/0_$`_P"*?QCWYK\G
M]>T'5?!_B/6-#U6QN=,\0Z7Q>6EW[>_?U_'\OZ(\%?`G*>"LV_UEQV<?VWG$
M(.$8*/+"":3ORW;4DTK/F22T45=W/K2Q=EHDG%VT;[VZ:7UMKU3>Q_IQ?\&Q
M,2G_`())?!Q3C_DIWQ>S]&UV<#COT[XX.#7YL?\`!Y`JI\&_V'U4YQ\8O'F>
M<G/_``A??_//6OP#_8A_:;_:N^&7[//A[PM\,OVJ/C[\+_`-KK'BC['X4\$^
M)-%TWPU8#/KXA\-GOSQ_]>O&/^"DOQR_:$^,>@_">R^-'QV^+/QC&A:QJO\`
M9'_"S/$>B:D="U0C!/\`Q(/#7A(9V]"02,!A@@5\UPYX0YSA?&M\9O,:/]E+
MB6MQ#HI>T]E4FI1IK9+6RE=-:77Q671_:,5BE@[-NR:TTNDKN_>VS[:=K_-_
M[`O[:GQ)_P""?7[4GP__`&G_`(3JMV-`.HVGC#PC>7:Z>/B5\,]9</XV\':V
M"3GQ&CHK^!F&"CZ`&7E1N_U.OV)OV_?V:/\`@H!\,M'^(OP%\;Z5K9^R+=>(
M_!6JWN/&_@C4B$W:/KF@E248$N%\2[G!`7Y]S83_`![)H?[2_P!!L8/M/^F#
M'T[^_P#^NOTB_9D^"?Q;^&.OZ?\`%3PY\4_B1\$_'%K_`,>=K\/=8UGPWXY.
MF'/_`!)=;UOP^%_M\8[?CP.!^A>-G@UP_P`:R>>4LU629ZTUS<O-[1)W2G%.
M+DDVW%J2E%MN_+*:?G_6GA+<UVF[MWVL_G;HM+NRONKG^E!\=/\`@D%_P3>_
M:3\=ZC\1OC+^R%\-/%?C:[.[4O$VG?\`"4^'=0U+4%49U+6/^$=N?"FARRHB
MEWEEC;<2S;R-J+]A?!7]GSX"?LK>!$^'WP1^&W@KX.^`M,M3?76E>$](CTC3
MI'5'$FJZUK#PL^NZV!@B7Q*\D_/WBBY;^)+P1_P59_X*#^"-"L/#EA^TQXK\
M67+'[&=7\5V/@SQ)JEB0,`D_\(USP`,^@`KXX_:N_:5_:\_:_P!&N-#^+7[6
MOQT&CW63_P`(GI&L:+X)\,\=/[<T+X?``]??C\:_F7#^!?'F;2CE&;\5<V3<
MUGSUJ]6'*FM8TI.,.9K2+33A=VNM)=']M8.W:]M;)=NKTMN_N[7/U-_X.#/^
M"V?@>X^'?BW]A+]DOQE!XJU[Q,&T7X[_`!@\*:O'J/AKP]I3#)^&.B:XN$/B
M/Q2@\OQGXF##_A#!D,SNP*?RI?\`!+ZSAO/^"B/[#6ESPVUQIY_:;\"_\2J[
MM/[1TW_D-9S_`&)V[G)Z'GFOF#XJ?!_QC\)=4M['Q'8_9O#]U_R!]6TFS_XE
MI]NO_P"KI5CX#:]XC\*_&[X;^(_#FN:WX2\4Z#X\TN]T?Q#I/']@ZI_\T70=
M/>O["X4\,LHX+\-Z_#?#4VZU>$_:U[1<YU)4U!U':U[)022Y4HQC%))('BU)
MIM1:5K+6V]WT>][_`(G^T>/`7@@@'_A#_"9R`<_V!I'I_P!<J7_A`?!'_0G^
M$_\`P0:0?_:5?YVTW[:_[>?FX'[<W[4/;@>._!N!CM_R3?I^&/PJ#_AMC]O/
M_H^7]J+_`,+OP9_\[BOXS?@3QG=WXHI[O15*_>.F_FON\RO[4PKZO7T\NR_K
M7L[_`.B@/`O@4?\`,H>$S]?#NC__`!JMG3=)TG1K7[-HNFZ;I]OVMM-LX]/&
M?3";!],A?\?\Y6;]M;]NT2D?\-S?M,?^%WX,[_3X;Y_+D]\UR_BK]JW]M_Q3
M8:AI-[^V_P#M5"WNN/M=IX[_`+,[8P!X>\-CC_\`70OH^<78M*$\[I<CY;_Q
MFK:7?+*KJUO>ZLT2\SP:5TUHKK;R\O/\?)G]Y'[7O[<?[,G[#OPWUWXG?M`_
M$[PYX3T[2[!KNQT&YOQJ/C77K\YVZ3H6@)GQ!([85EPH"ASC8,H?\I'_`(*`
M?M:^*OV^?VJ_BM^TWXOLM2T2#XG7FIV?AK2KN\S_`&!\,-!QH6@Z+R,Y!Z^I
MSQBO3_CQ^S=\3?&U_J'Q&G^*GC_XQ^(?^?OXF^,-9\2>)O[+ZXT/7/$!]O3K
MS]?SOO+,P_Z#/8W/VC3-8_TS^UCV)QV_^M_A_3/@MX(<.\&<V-Q^;?VWG-2#
MIZ)*,(22NHQ;=ELY-MR=K-\L8Q7.L2LST5K*S?2]K;N_DM5Y][O_`%0?^")'
M_!1SX9?MT?L=?!W2H/$&E67QV^&O@;2?`OQ3^'PU,)J>_P`$1QZ!_;FD893)
MX?E`5UDP"R$*6P$+_:7[2?\`P3J_8H_;!U2PUW]IG]FWX<_%SQ+ID>GV=IXD
MUVSU2P\1'3PV2=5UK0&\,3<'?MB9W1`!&J@`*/\`*\_97^#7Q-@O]/\`C%H?
MQ&\?_":X-Y]BT?5OA[XDUGPWXGO^,<:[H'(^GZ'BOVGT?]KG]M_3K6WL8/VV
M/VJK?[+_`*%]L/CO1M2SJ@Z`_P#%-Y_4^HK\<XM^CS5P?%N:XW@WBQ0C.<I\
MJE5I3A*<W4FHU:4XM13E:--1]U:*4E:*Z%G6$PRU5VK)VU3T5]/5=];K5=/[
M$!_P09_X)#12"8?L)_";,`)4_:_B)D?0?\)$01]-W?\`#[7_`&8/V1/V=/V.
M_`VH?#_]FGX/Z!\'?!>I^(K_`,2WOAWPG>ZO?:;>ZO)C=JY.NS3,KL,;0IVY
MV['?K7\%_P#PVM^WH>O[=O[4'_A=>#/_`)VM0?\`#:/[=L,7_)\W[2]K;VI_
MZ'SP9_\`.VQ_]:ODLP\">/\`,\$UCN/9U*?NWC6Q&)KW2=[)5Y5$FFDDU?7?
M9#_MK!NUUK_AC%/;LE_774_;;_@[F(/["GP0`.2/VC8\\YP?[%\0<?IG\:_$
M?_@TF('_``4D^(9)P/\`AFSQ\,GW\:^`@/U-?`/_``43_:"_:2^+/PJT#1/C
M!^T7\=/C#X8MO'@O;72?B9J^BZCX9L=4&BY']B?\(]X;\(YQSC/0'TKYA_X)
MY_$SXO\`PF^.VOZI\)/B=XX^#WBBZ\!ZI9/K_P`--6T73/$@TL:TI&BZW_PD
M'AUBW.>JC`4'DDA?WWAKPNS+`^!>;<'O-:3KYTZTH22E[-2E4G*DI:\RM%P5
M1]9<W+T.7ZS'ZVL6KN-K.WHD]KI=;-]+:WW_`-.#_@LRB_\`#K7]MU?+&3\$
M_$Q5>N<ZOH_/'<A<]1]W`Q7^1=Y/[K_..GUST[_IFOZ)_P!I;]K[]M#QA\`_
MBOX=\<?M3_M"^+/"%SX;-GK'A3Q7XC\&?\3[2R.?[</A_P`-_P#(NGOT_'&:
M_G8FA_=?A_+^GZGK7O?1U\-\PX'PF;X3,,TIMYW-2@J7,E&*A35I<S;YN:+N
MU9./+=71U/$K%VM>UEO:][_\'SZW/[)?^#-[_DM?[<P)Z_"W]G8+G@;CXR^+
MO?ITK^@S_@Y&(_X=`?M4#(+";X8GKG@_%'P%_P#6K_/W_P""</QE^,_PE\;?
M%^7X%?&CQM\%-0\4:/I5I>7GP^U?1M.U._&B:QKV/[<_X2#PXRX&20=JM\QW
M=0%^S?VV/VF?VL_'G[.WQ`\(?$[]ICXZ?$CP#KMWX86\\+?$+Q%HO_"-WVI:
M(064?\(_X;!P2JD@D*Q5<]`:^$XV\&LZS7QGAQ?'-:7LXXFA6M)2<N6DZ;E;
M5^^U!.#[/6R.=9W@\-[MG=WLDEN[+JGI9W[V=^B2_`F;]S%<?N/M(_Y]/^?_
M`*YX_IVQFO\`2'_X-N?^"BG@'XZ?L8^!/V1O%/BK1]-^._[-:_\`"L=(T'4]
M46Q?XC?##05(\":]H2')=5\.`>&-BJYW>'S\C`G'^;QY,_\`R[_9K>X]./Y?
M3CZ5]4?LQ_"#QQXPUZW^)WASQ5XD^%T&A7FF?V/XL\*:QK/AOQ-8:IH><_V)
MKOA__D7SCGU'!SDU^S>,GAIE7B#P?2P>*S7V=:ARSH3:NJ=54W!-Q37-!J<H
MRBI)N,GRRC-1E'H6*^JVWL]UU[[I/7MOJEHS_7%_:/\`V2?V;/VM_#$/A']I
M'X*^"OB[X?TRX8Z9;^+;5C]B;4BB-_8>K:(T>N6I<KIJRE&@5BB,2WEG9_%G
M_P`'*/\`P3>_8C_8B_9Z_9R\7_LL_L_^&?@MXG\8?%WQ-I^M:KX;?QCJIO=.
M_P"$0T8NKZ-KWB'Q4I`*I\GEJR.KEP203\K>'/VL_P!MCPMI>GZ58_MO_M56
M^D:59_8OMA\>:+J1]/\`B>:YXA\-^]?`W_!1K]H/X^_%/P)\+X?C1^T7\8OC
M'H&A?$C5+W2+7QOJXU+3+'5/[$Q_Q)/^$?\`#7A')P>/QK^;?#?PBXQX?XNR
MG$X7BM?5LEJR<Z<95HTY4Y4Y1</8N<J2;G)3EHTVY2UFE)BS+"-:VV5M$[.\
M>MNG3M]Y^WW_``;R?\%M_`?P8\-:!^P-^V!XPM_"_A[3;UK+]G+XQ7]Z+_P7
M9IAW7X,ZUK9+(=#\+'"^"/$[RJF&/@@S?)X,$G]H7COX4_`']J?P-90?$3P/
M\*_CCX"O3?W.B_\`"0:9HWQ&TUAJZG2FU;0-6G25-#:>.-XYI/#3+(L1<Q3)
M)S7^.#\,/A#XD^*>M:AHOA2RM]1ATIMUW>W=J1IUAIH)(.MZ)U!R<Y!SGGKC
M'[(?L^6?[1O[-]C!8^`/VMOVC_!-N;/_`$WP]X'\=ZQIGABP_P"P'H6O_P#"
M7`#IV'<]>OUOB;]';*\7Q"^(^&>*UD><5'SSB^9WJ.SE*FZ<H2I2<GS<R;LV
MW",>J6=87#)*UG9+3=JVS2C9]FTORT_T!I?^"-G_``3%F<W%Q^Q1\#KF>;[S
M6?AO4=.)&.2P&O84_0#->9_%O_@CY_P31T;X5?$W6=)_8Q^"UA>Z;\./&][8
MW5KHVIB^L]2TSPCK:Q%777MQP,I'M?#!AO.2DB_R%P_MK_MV^4;*#]M_]J*V
MM[7_`)>[SQYX,_\`G;^GUZ<5C>*_VT/VY;WP[XGLK[]MC]H_4K"Y\.:K9W6D
MW?B_1?[-OM,.BG.C:W_Q;;@\D$\'!(R:_,L)X->).%Q])RX_JR4:L)-_7,:D
MXQG%OX:BNW%.Z;LW[K?*[JEF>%>W+KTY(O=>C[]]-;;'\Q1F\ZU_U/\`I'_$
MT-H/^0C_`,2P:-H/OSQSG/!)7J.:LW^JG^G]33X9IC:?;?\`2+DW5GJ9O+;[
M'I&FY_XG)_XG'IR3@DKG(!W!<FFS?\O'[C\_R'?\?S(K_0O#X9QX?<92O*-!
MIOK)^SMS7\_GUOT)6)O;2U[=)=;:[>:WL?[)/[%O_)G7[)O_`&;1\"/_`%5O
MA6BC]BW_`),Z_9-_[-H^!'_JK?"M%?X\Y@K8_'+MC,2O_*TSZB'P1_PQ_)'^
M-M1/V_#^M%$_;\/ZU_L7+X9>C_(\"6S]'^1^W'P8'_%H/@_.8?\`F0_`>?Z\
MC^7XUYO\>/VA=5^#.L^']*@\':)K>GZIH_\`;7VN[O/7H/RSUZ?3->D?!G_D
MC_PH_P"Q!\!?^@U\7_MKZ;?:EXR\#WVE6.I7-O\`\(WR-)T?^TO\X_7K7Y3@
M,-E6:9NUC&UK9-NU]M[VO_6[T/B,!_R-6GYZ/_@_(L_\-O>)/^B9:)_X.1_A
M5_1_VZO.NM/@\1_#FV_L_K_Q*;SO^?`Q].O?BOA?^P=<_P"A<\3?^$AK-:&C
M^"/&.O2Z?I6E>%?%H.J?]2Y_DU]D\EX=2;4MD^ODO3^EZ'IO+L)>]^M]5IT_
MX'X=M?W(T>\L-8TNWU6W_P")EI^O:.-:LKNTZV'^>V?UZ5^?_P"V]X;L;/Q'
MX&\8V,%M_:&O?\26\_Z?_H/\X[^M?='P]T'5?"OP^\#^'-5GMKG6/"_AO^Q?
M]$_GQQ[=:^#_`-M[7K&:_P#A_P"'+&^M?[0TO_B=:P/3USUX'H.WZ?*</)_V
MLU@K\EVM=]]?PM^/F>;EUUFJWY5]VGX?\$^B/V4O^2(^'IX/^?SQ1_\`K_ER
M#^/IX_\`MZYFT?P/YQ^T'^V#R>.,8_\`K>G/Y>O_`+*?_)$O#_\`U]^*/YUY
M!^W=_P`@#P/_`-AC_"O1R;_DK&NS@K?^`Z6/0_YFL?1?G$\G_9+^&.E>*O'F
ML>*M5L?M.C^#='/2S/\`9G_"4'IW_+IQ7Z<>-O&&A_#[P[X@\4ZW/]FL-"M/
MMG<Y)';U)Y`KX_\`V)]-\GX9^*+[_EXNM9_TSZ_CW]?UKH/VQM1OK3X0W%O!
M"/L^O>(_#&C'\`3Q[GH.._O59Y;&<1?5'JN;7M9VL^S_`#VWL5B9+%XOZHVD
MM[NWKJ_E\M=['ROXJ_:Z^*FO:IJ%]I5]HFB:1_RY6GV/^TOL'?V_S[5]'_L]
M_M.ZW\2->_X0?Q_!;?VQG[;9W=I_R#+_`/#I_GH:_,CR?^/C]QZX_ICCZXKT
MGX5ZE?:;\5?A_JMC_P`?%KXPTNRO/S_SZ#TZ5]%F7#>4X3!/&6=^7SWLM7;_
M`"U25CT\QRW"?V2M-4_5K;MKWOKMV/UW^+7@/2OB=X#\4>%;WBX_L?\`XD]W
M_P!`'W]^>G3ZXQG\9_"NL3^#_%MOJM]I?^D:!J_VV\M#_P!0+_B1'W'K]>23
MSG]Z/)A_TC]QZ?X#_P"O7X3_`!4TV#3?B7XX^PS_`/,X:I_]?T[\CMZ5YW`N
M(OS1DKK;7L[=_P`4_0\S+MEZ?H?7$W[;VJ_]"!;=1_R^>W]?\XZ43?MO7W_0
M@6W_`(&<Y^G^<]>U?!\-E?3R^1!!_:1_Q_F#^'>MB'PKXJFM?/\`^$5\276G
M]/M=IX/UGT/KSWKTI</90VW=:MO6ZWU_7\N^G1]6P7=_A_GYK[S[8F_;>U7-
MQ_Q0%M_X&>X^G7M^?O78>%?VWM)U'5-/L?%7@#4M-M_^7.[M+PC[!_G_`"/3
M\_YO!_C&'KX.\2?^"?6?IV\-UT_@_P"$OQ-\5:II^E:5X5\26MO=?\O5WX;_
M`+-^P<YZYX]_\X\MY/DZ3M-+1V]Y=%Z+M^7;7G_L["=)/^K?Y_BOG^W/E":Z
M^V^?_:6GW5I]M^UVG^?U_P#K5^3_`.UUX/L?"OQ1U#[#]FMK?Q19_;?]+_J?
M;IGT]J_5C3=-_L?1O#]CY]M<_P!E^&_[&]O0_P!1T'UK\UOVY;S_`(N-X?@@
MP=0TOPW_`*9_0=O3UKY_A3_D:OEUUE;K_+;]`RZ_UMX-;6NGT_#NN_4_1GP=
MIL&F^$O#^E6/^C?V7X;\+WOU_P")+_C[?G7Q!^T)^T)\0/AQ\0K_`,*>%?[$
MT/3],M!>_9#I']I"_P#Q)``]R0,]\5[?^SK\2-*^)'@/1])-]IH\0Z#9_P!B
MWEI=WA_M._STQW_R>YKUCQM\+/`/Q"ET^?Q3X5T36]0M;/[%_:W_`"#?L'].
M<_\`UZ3P^$PN;MYKE;:;U:;:W5F[:M_=MT/-P\7E>;-XM-IZ+1N*N]+]_P#/
MY'Y;Q?M:?'>'_F*Z(?\`N#YQZ^N/Q_I7W1^R[\0O$?Q.\!ZAXC\9:K_;>L6N
ML:I9?\>?]F#K^?X?I70?\,O?`[_H2+7_`,"M9_PKTCP3\/?#GPWT;4/#GA72
MK;1-/NKS[;^G0C/Y_P"-;YUF&48G!K"82-ETTV>G6RZ^J\];'3F6(PFC2_#J
M]5??YGR_^W'_`,DZ\/?]C=_6O#OV,H?^+H:A`?\`CW_X0/U_ZC>..>@_'OZY
MKWG]N;_DFOA__L<!7@_[&O\`R52X_P"Q#'_IZ-=.&TX<7:TO_2HV_#8ZLN_Y
M%'_;VE]]UI^&WD?<'QSA@_X5!\2,P?\`,GC)QT^G?_&OQ7O/W-K<#'/V/KW]
M/0]S[?3!K]K_`(Y_\D<^)/\`V)W]!7XDW?\`QZS_`+C_`)<\`]<'U[?_`%\9
MKKX#Z^7+;RVO;]3T<NW7K^I][_L6Q?\`%4?%B#_ISTL?^5K7S^M?2'[5T,'_
M``I;QAC[-_Q^:7CMV'K[<^_UYKYN_8L_Y&[XP?\`7EI7_IYUZOIK]J__`)(M
MXQ_Z^]+_`)BN7.6_]9-WM%_C"[^[<\W$)?VK'1?U*'_!_$_'[_EK;SS_`&;[
M/G_3!_G\^G3(K]H/V>]'@T'X.?">"Q./^*/TJ]SU^W_V[_;_`$^G^%?BO-#^
MZ_Y=L_8\?Y]?QX'8U^V'P9A_XM+\+^O_`"3?POCO_P`P77__`*W7D=37H\=V
M6#I[)7C>UO[GR_X)TYEM)]._0\/_`&HOC]XJ^%>LZ?X5\#_9K;Q!=6?]M7FK
M&S_X\-+X^GK]>AS7P?X\^-GQ&^(6EV]CXCOK;4O^$7_TVS_T/^S>!CV_+CTZ
M5ZQ^V!_R6JX_[!/]!7R]IL,%Y?V\$_\`Q[W5YI?VS_#/U./_`-5>CPYEN#63
MO&I:VU^>UO+=VMV^3PV&_P"$E.VNK3LM-=O+TO\`=L_V1^`_P]TKX;_"_1[&
MRL;FYU#5+/\`X2?6+O\`YB><<_T_G7E_[2'[0FJ_"76=/\#^%=#TW4O%'V/^
MVKS5KOC[!I9]3^?<U]@0V<%F;>QL?]&@M;/2_3_H"_0?7GOZ=_/_`!5\)?A7
MXJU[^W-<\#^&];U#[']BO+N[LM9_3.<=?K^5?"4,1A99P_KB<M6TK.6WG;5N
MRW^;V/"M?&VM?R^1^<\_[77QPFZS^&__``FQ_G\/3Z57F_:T^--Y%<03S^&O
ML]U9_P"F8\-G_D%__JZ?_JK]"/\`AG?X'_\`1+/!/_@$:Q]=_9[^"T&@^()[
M'X9>$K:XM=&U2]L[NTL_^/#_`(DOXX]>*]K#YOE+DE_95W>R=I;W6NJZZ=CU
M%B<)=>Z[W732^GEYK[S\</W\-K;_`&Z#[3J%K_:GVS/_`%'<_P"<=OTJM-#F
M*XZ>W;OVZ_Y^@I9O/'V_R(/LVGVNL:I98].?7_/Z4V;_`%4_T_J:^XJZY94?
M>E/3_MUGT:2LM.B_3_)?<?[)7[%O_)G7[)O_`&;1\"/_`%5OA6BC]BW_`),Z
M_9-_[-H^!'_JK?"M%?X\9C_R,,=_V&8K_P!/S/?A\$?\,?R1_C;4LW^I/T'\
MJ2B?M^']:_V+EL_1_D>"?MQ\'_\`DD'PP_[$/P)_-:]0FA\[_EW-SS_SY@\^
M_P!>E>7_``9_Y)-\-_\`L0_`M?)_[8WBKQ5X5\1^#X-*U76]$_M/1^/[(UC]
M#_GGM7Y1AL-]:SAI:/577HOGI^=V?)+#_6,V5G;>_FM-?RMZGZ`?9/\`IQ_\
MD_\`Z]6#"(<>1!]F^R_\O?\`GW]^M?A/_P`+-^(W_10/$G_@8?\`&MCPK\;/
MC%X5NM/OM)\<:W]OZ&TN[SG]._3K@Y_&OHY<+8RS?/I9NW-T[=_U.K^SGV?]
M?\,ON/V8^(4WC&S\):A?^!]#T34O&%J1_8]I=WA_QQUQWSU^M?B/XJUCQ'KW
MBWQ!?>,?M(\0?VQC6/[6L_\`CPR3_P#6K]L/"NI3^)?"6C>,)M*N=-N/%&CC
M6OLG_/AZ_P"<_CW'Y\?ML>$+'1_&7A?Q58V1^S>,=(-EJX]_`V,_F!R>^`.2
M!7G<+8CZIC98-JSOHVMVOSZ=NGH1EUEC'A--=;Z)_P">JZNVI]+?LI_\D2\/
M_P#7WXH_G7D'[=W_`"`/`_\`V&/\*]@_9+AGG^"/A_\`<#_C\\4'TX_I_P#J
M^E>/_MX0_P#$F\#_`+CKK''Z_P"3TR.Q[].7W_UKEO;7\Z?Z7_$&G_:RZV2_
M.)7_`&(?%5C9R^,/!U]!_P`3C5+/_A)]'M/P';(_KV'2OJCX\?#>?XG_``Y\
M4>'-*@^RZQ]C^VZ/]/Y_AZ]#BOQP\$^)-5\$^*-'\5:'?&VUC2]8^VW=K=\8
MTS@\]<C!Q[9STP#^N_PK^.7@?XJ:?IXL;ZVT3Q1_R^>'M6O/^)F?^Q'Z_P#"
M0<=N>*,[R[%X7&?7<&M4[M[Z:/3K;?IZ>;S'+6L6L9KI:UNMOQZ;Z7VV/QPU
MC1]5T?4-0TK58-2TV_TO_H+6?;`_G_D>OT_^RE\']<\8?$'3O&4^E?9O"_A>
M\-Z=6U;G^WN2/Y<\>O6OU'U+PKX<UB4SZKX<T36[CI]KN]'^@'U[=O\`"M'4
MIM#\-VOG7U]IOAO1]+P?^)M>'31_//\`]>C$<48[%X-8+DE>R6SMT2OI]W^0
MO[8DTHM.UK;2MM;JM/\`@%?4M2@T?1M8U6>?[-;Z7H__`!]W?_+_`/E[_AUK
M\1]'T?7/BU\2[C0]*'_$P\9>,-4O/M=G_P`P$?7_``_Q%?2'[2'[2%CXJM;C
MP/X(OO\`BG_M@_MB[Y_XGW7IWZGU]JY[]C/3;&\^+5SJL_\`S"_#>J7O?@_Y
MXQ]*WR[#XO*L&\9B]--+7>]M;=;?\.=6'P_U7"?7+ZO6V^_RZ_?I\C[Y^'GP
M3^'/PQTO3X-*\.:;<ZAQ_;'B'5N=3O\`C^F<?@<XKVCR?)A_<0?9K?/_`"Z=
M3T_SQ_\`6JOJ4OV.UU"^\C[3<6MIJEY_G^G?CKWK\1_&OQ@^)OC;Q'<:Y?>(
M];M;>ZO/]#M+36?[-_L'MU`SWZY%>/E^&QN:MVS5ZOOHEHO\[=OS\W#8=XMM
MMZWOIIVO;3TVWLC]O_)F_P"GG\S2^3/#^_@^TVUP?^7O!Q[^_/\`GW_!?_A-
MO'/_`$.7B;_P<43>*O%5YS_PD?B7_P`'';^7;^E>FN`V]\V?FM?+3?\`3OW9
MU?V:^S_K_AE]Q^U'C#XD>!_A[H.H:YXCUS1+:X_Z%[_F9K_K_P`P/Z_YS7XT
M?%/XAW_Q-^(.K^*KZWN=.&O$6?ARZS@6.E@]#C!`^A!P3TR:XZ::>\/[^>YN
M;CH;N[S^`_\`KT?\M/\`M\_]EKZ+)<DPF5;WD[*_>6WGU[JVK6FQT85?5&KK
M7TUZ7]/+;<+2\GTVZ\^QG_LVX_X_3]DO/[-[>Q'T_P`:](B^/'Q;L[7R+?XC
M^+=,]/\`3-&U+_/7O[?2OOC]D7PW8:Q\(//U7PKINI7'_"2ZI_I?V/\`M+\_
MU_G7U!_PA_A7_H3O#?'3[)X;]_\`'IU_/FO-S+B'"X;%_5'E/,MG)QOH[:\U
MK_Y:?-YCF-VFHWU3O:]_N7S5_6VQ^.__``T5\:;SBQ^(WB2YS_RZ?8]&]^G/
MJ?3\J_3G]G7_`(6/>?#[3]<^(T^MZWK&J7G^AVGB$_V;]@_//<_I7L]IX/\`
M#FF?\@GPKHEMZ_Z'G^?TKGO%7C#PKX/L//\`%6N:)HFG^NK:Q_Q,_P`!_2OF
M\QQ^%S3"_5,'E+6UI<K3WB[[*]^O_#(Y<17^M)>[>Z2VMV^6UM/TLCY(_;>F
M\GP;X'M_^7C7M8U3K]?\]>_MR?'_`-C/_DK>H?\`8AC_`-/+5Y?\<OC-_P`+
M:\;VU]8P?9O!_A?_`$+1M)U;&FZE?Y_YC7YX_P`FO3_V+89_^%H:P/(_T@>`
M_P#]?]?\BOHXX;ZKPZHXN+;MHDG>^BM97Z:=M.VH_J\EA%A-='?KY.][=]/G
M9)=?N?XX_P#)&_B!_P!BV*_%G['?=/(N;;'0_P!C_P">X[U_01-9^='Y$]C]
MI_[<^W/X=._?M5?^P;+_`*!=K_X!"OG<MXAGE:TRE]T[6WZ[;7U_4,+B'A>F
MUDKZWVMW[_+TT/@?]B?P?JMG%XX\5:Y!=:;H^J#%G:7=F=.U._&>.HX^F/>O
M:/VM+RQL_@9X@GN/^/BZUC2[+U/Y?YZ#\?>-8U+0_"EKY^N7UMHFGVI_X^]6
MO.+#_(__`%=*_-?]JCXV:'XVNO"W@[PK/]I\+Z#>?;;R[X_T_5/^@U]/Q_'O
M1ERQN:YN\;*+23OM:UK>2V7KLA*^*S5:.R5]FKW2Z^5OGWZ'Q?-_R\_\`K]P
M/@G#_P`6E^$_K_P@?A?M_P!077_?CC'^37@_[)?@GPYK'P6T^^U7PYX;ULW6
ML:I_I>K:/]>>G;U]NE?7%GIMC96%OI5C97.B:?:_\>=I:6?XY^O^>QKIXTQ#
MQ.%CA+.Z<==F]5W\QYCF+6$>$LUJKZ>G7\C\K_VS,P_&ZX_[`_\`CG/7I^/;
MFOE?R?.F\C\_Q]_\.^?K7[X7O@GP=K%UYVJ>#M%UNYZ_:[O1_;_.?\,5\3_M
MF>%/#?AOP1X7OM*T/3=,^U:Q_P`>EIHX`O\`\?ITYZC\:]CAK.7BH+)[-+EM
M=)V^&-O+^MQ99F+Q*^IV=DE9ZV>VO9>7D?6_@[Q58^*O!OA_QCI7^DW'BC1]
M+UK[)W_Z`/Z_A7QQ^U1XD^-/@GQE<:YX<\5>+-,\'W6CZ79?:])_Y!=AJF?^
M0+Z#UKS_`/9O_:$@^'MK<>`/'$'VGP?=7GVW1]6M.N@^FB\8[YK](-&UCP=X
MVL+>?0]5T3Q)I]U9\6EI>#4O?'<@?Y]J\7%83%Y%C'C.7F3O>ZO=-K;1]-[O
MJ%GA<7];L^UM7O:]_N/QP_X:`^,7_13-;_\`!P/_`)G*2;X_?%R8'[=\1M;N
M;>Z_X_+3[9TQ_P!RWZ_X^F?V7_X0[0O^@'IW_@F_^M6!XJ\*:'!X7\43P>'-
M-_Y%OQ1_S!_^H*>,?KTKKPO$&&;2_LEW?+KR[7:UVUW?W+L4L1JM.JZ>:[Q]
M/P/PGFFOIHKC[=.;G[5>"]]_T_\`UX_.IYO]5/\`3^IJQ-"?M>H?N./[9U3_
M`">O'_U^35>;_53_`$_J:^XQCO1J/O3D_P#R69]%'9>B_(_V2OV+?^3.OV3?
M^S:/@1_ZJWPK11^Q;_R9U^R;_P!FT?`C_P!5;X5HK_'?,?\`D88[_L,Q7_I^
M9[\/@C_AC^2/\;:B?M^']:*6;_4GZ#^5?[%O9]=&>#Z'[;_!?_DC/P?_`.Q#
M\!_SKQ_]HKX`^*OC!K/A?5?#FJZ;;?V7H_\`S%L_YX]<_C5?X8_M'_!?PY\.
M?`^AZYXXTW1-1TOPY_8FL?Z'XRSG/'3GGL*](_X:6^`__11=-_\`":\95^98
ME9QEF->+P>4N>MW:+;UM;;5=]>S]7\1;-O[6;2>][V_'33:VWY'Q?_PQ#\3O
M^@GX1_\``*M#1_V(O&,U_H_]N>,=$MM/_P"H39_GS^'\Z^P/^&EO@/\`]%%T
MW_PFO&58]Y^U%\`8?^9__M+_`+EOQE_G\O\`]?0\ZXBM9Y6TVKV>^MM=;>7X
M'3_:.;7L_1^ZEV_NJVWRT['T!INCV.FZ7I_ARQL?LVGZ7H_'VOZ<9_,'_//Y
MS_MU>)-*O->\'^%=*_Y"&@Z/_;6L?IZ?3IVKUCQA^VEX&TVPU"Q\':5J7BW4
M/^HM_C_*OS/\2>)/$?B/Q'J'B/7+[^TO%&J:Q_;1U;ICK_AT/7CVKT>%<DQG
MUMX[-XV;ORJV^S2[[[/\SIRW+I/%?6W>[U?J[:?\%GU!\,?V;_'_`,3O"6G^
M*]#\?Z;X;T?7M8.B\6>M'_ZQ_3%<?\;/@SXX^&-AX7G\1^*M-\2?VIK']B_\
M2FS_`+2''?\`+Z=/PKZ@_9U^,WPD\$_"K1]#\5>([;3O$']L?VU]D&C\_P"?
MUXKS?]KKXD?#GXA:7X'@\#:[;:EJ&@ZP=:/V31_Q]<$?_6]*Z77S59N[95[J
M5G*UK1Z-O1)6MOKTOT.E+$7]7:]G^/\`PY\3^3_RW_#=^F<_Y^O:D_U,OGP'
M[-<6O_'EGI8?3O\`R_.E_P"67^?[M%?66;M[M[]+7]4NY[:V5^RO?]3N+/XG
M?$:SM?L-EXX\6Z;I]J?^735_[2R/\/Z_ICZGXJ\4^)+O[;XCO];U/4!P+75M
M8Z^G8'CZ#`[9KG_(]_U_^M1-#_D_Y_(X]012Y(K["\_=7^1R?5(_W?N8?\LO
M\_W:^F/V2_%5CH/QDT?[>/[-M]>L_P"Q;/ITZ=\G_'^?S/5B&:>&6WG@_P"/
MBTO/MMG_`$XX/]1SSTKGS+#+%X)X16M9V::LVE;H[>MK[G'9M<MFD]+;>7IU
M1_01-#!-%^_@S_/O@_Y_05^=_CO]B&^U'6;G5/`'BFUTVWN]7U36AI.KZ.>.
M?8]>,<YZGN!5GX;_`+:.E?9;#0_BIH>M7.`+*S\0Z3:#)SQP"03]!G'4C%>_
M0_M1?`B\M?M$_C_[-_V%_#?/'7I7YBL+Q!E3_P!CBVD]=+Z76C[WVZ_D<3R[
M%Y6^9/=WLGY)VNM;]UIO8^0/^&(?B=_T$_"/_@%1_P`,/_$S_H.>$_\`P"/_
M`,37VA-^TM\"/^BC:;V/_(M^,N_!_/J:/^&EO@/_`-%%TW_PFO&5>U_;/$44
MKY4U:UV[JWGL<RS'-M$O)*Z7E_=\OR[:_%__``PW\5)OW'_"5>$?_`/I_G./
M_KU\KZQH]]X6UG6-#OI[:YU#0=8U31;PZ3_/]/?IZCG]>/\`AI;X$>;C_A8V
MF>G_`"!_&6/_`-?MU[8Q7Y+_`!"O-*U+QOXPOM*OK;4O#]UXDU76K.[M#C/]
MN\]?<C.>/IUKZ/)<1FV*UQB4;Z:JR2LOUOOK]^GMY:L6W?-DNC5ODUY?/_,Y
M>'7M;TV+R()[FV]?LEX/7WXZ&K7_``DGBO\`Z&/4O_`P?XUF^1[_`*__`%J/
M(]_U_P#K5[/*GKRIOO9/\?FOO/2LNR^Y%C^W?$'_`$'-2_\``W_Z]$TT\V#?
M3W-S_P!??;W_`!__`%Y[5Z*2C%/2,4_)),++LON#R?\`EO\`AN_3.?\`/U[5
M8AGGLY?/L)[FVN/^G2\_LW_ZWKZ?6J]%5:ZLU==K:=.GS7X!9=E]W]=E]QH?
M\)+XC_Z&74O_``,/^%'_``DOB/\`Z&74O_`P_P"%9]'D>_Z__6I*FG>T$[;V
MBG;UTTT1R_55_=_'^NB^XL37E]>1'S[ZYN?^OJ]/^'^0>*K^3_TP_P`_]]T4
M5TQ44U9):J]DEVW_``.I)+9>1H0Z]KEG]HL8)]2MK?'V+_0[SU)_G_GUK]N/
M@^/.^$OPOGGF-S<77PW\+]/^P+K_`%[_`%Q^%?AO-#YT7D?\_7?MUQ[_`./0
M]Z_5CX;_`+2'P6TWX?>!_#?B3QQINFZCI?AOPO97N/#GC(CC1=?!Z'![=^:^
M4XTPN+Q5OJD=5RWT\U?TTZO3:_8\/,DO>T7W=/ZL?*W[76O:KIOQDN((+ZYM
MK?\`L?\`Y=+SWY].OI_7%?+$VLZ[>?Z/>WUS<\_\O=Y_GI_^JOH?]J+QMX.^
M(7Q5_P"$C\'7UMJ6CW6C_8K.[L]'[:%P>/S_`,.:^:*]+AQ1CE2345/FUT2E
MHU?SMN=>6)+*]DI7[:[*_GZEC_EC_P!.W_U_SZ?YQ5B&:>S_`']C/<VW7_CT
MO?[-Y[=_2J]%>CR\VG+S65[6O9=[=O,]!)-*Z3T73R1H?\)+XC_Z&74O_`P_
MX43:]XCFBN+>?7;FYM_>\]<_3IZ_TK/\CW_7_P"M1Y'O^O\`]:IY8](QT\EI
MM_P/P.;ZJO[OX_UT7W!_RR_S_=I)O]5/]/ZFEI)O]5/]/ZFECOX=7_!/_P!)
MF=>Q_LE?L6_\F=?LF_\`9M'P(_\`56^%:*/V+?\`DSK]DW_LVCX$?^JM\*T5
M_CMF/_(PQW_89BO_`$_,]Z'P1_PQ_)'^-M1/V_#^M%+-_J3]!_*O]BJC:A-Q
M=I*$FGV:3:?WG@G]D?[$W_!KA\)OVL/V3_@)^TSKG[67Q3\$:O\`'3X6>%_B
M!=^%=*\">#-NAGQU&CA%!8N0%<*"1@;6!;(KZB'_``9S_!DDK_PW'\:01Q_R
M3GP9D_T[?YQ7[=?\$Z-/O-;_`."(G[+^F:/9R7^JZY^P5X3T31],TXA?MTDO
MPO6")(R<#S)I)%B4$[F,GEJ&9P!_F_:;_P`$L?\`@J=]FM[>;]A/]M_[2+3%
MZ/\`A4'Q*SD#)!YR,<<''TK^#.%^->.N*^)..\%B_&VEP+'(\9B*<(8FC3J>
MUA'$5(4Z-+EJ4+.*BE&3YY344Y7;;.KEBG\-_=5FGM[JN[V?S72_0_?K]KC_
M`(-/?C=\%_ASXW^*7[-O[0=C^T1K.BVLFL+\*?%'PU?PWXWU`J5D76?!OC<?
M$62$>/08BR*PB5Y&4"1CY2UXW_P2E_X-XOAI_P`%$OV+?#_[66K?M/>/_AA>
M^,-7\4:,?"WA3P+X-$8/@AR@4<Y+,06P,CCYL$H&_KI_X(F_"G]HCX(_\$R_
M@#\.OVJ;+Q+I?Q=T)?B=?7WA/Q9JH;Q)X'\,MXW\<KX$\'ZVP`8F'PYL!8?*
MJR+EF,9"^2?\&]MYX5U[_@G?JVJ>#!IP^&VJ?M9?MCWO@<Z6H&/";?'_`,1G
MP/L'4YT`(#C^`HW!)%?%X_QU\0\+AN),%#BM9VLCXGHY"^)J.1TG/$TI2J)1
MBYTZJIQK1I/EFD[MSC"?N2D<JPE-2ORKWKM:::<NM[>=E;RNKV1_EJVDANK&
MPO".;BT-X>^".",C/3GVYY]YZ_M$^#G[,W_!J9HGCOP3^RG>^+_B+\=/C%?>
M)-)^&=KX^\8>)/VKM*\.:Y\3V<>!F!D^'J_"GX7;O^$AYQ$FTG*"4QMOKY'_
M`.#@#_@C)\#/^";/A'X4_M!?LR7_`(DT[X8?$/Q\GPG\2_#7QKXC?Q)J/@_Q
MUH_@KQYXZ\$>,?!7C1W/Q%"2CP5XS$ZR&4/Y<`+(CE#_`%IP_P".^08G,\JX
M;SK)^)\DSC.*47PY7XCBH4)OEBW)6O))^\[2CHK)VDXP:U44URMZ72;2ULK[
M/2[2ZNVJO:Q_+G_T\?K^G_UNOO[T>5#Z?H?\*_M'_9#_`."3?_!&GX.?L.>'
M?VJ/^"A_Q>T+XF^-=:^#>E?&?Q5X8TOX^W'AO_A!_#OC?15\>>"_!?@WP-X`
M^($/Q'?QZGAN2U,)%W*UVYNU58_LLKMZ-^QQ^RG_`,&Q_P#P4U\8>)_@3^S;
M\%OCCX/^*N@^'-4\3V6E>(/BK^TGI^JG2=$/EOK?@L^(/C;\6/AGK@0@DJTC
MDQ_,$^<9\_,OI)<(X+&YE#!9/Q/GF6Y+5=+B3B**2R%N$W"4H*;A[GNMQE>T
MXI./,I0YJ2;:5XIO;6][JZ2TU?2WKV/X<O\`EE_G^[17]%_C+_@D3\-?V8?^
M"XO[//\`P3_^(6J^(OBM\!OC'<^&O%-E;ZOJVL^#O$GBOX8^.E\>:)K.B^-?
M&GP^\B4E/$_@5B626)I$(C!BRQ;]S/VV_P#@E7_P;O?L"3?#7XC?M/:9\2?A
MQX"\5/XD\-:1\*M`^)_[2GC?4/'WBB-USK2)X>\4/\353X71^:R'S=J?\)#%
MYL4NQDKIS'Z1?!^%QF78/"Y3Q+G?]LTHUN&_]7.5.,'NIQTJ)Z2=I1^RTW&6
MB5GY;V5W][=DTEKYG\`E%?VM?\%3/^"('[`'@_\`8*/[=?["ND>)/AOI^FZ3
MX'^(-CI=UXY^,/C/PS\6/A;XW9%1==T/X@32^*?`32KKAD5T`4("LB12`JWV
MQ\>/^"#O_!%CX7_LI>'?VB?BQ;^._P!G+PWH.@_"+QK\4OBOIWQ<^,/B]1I^
MNR>'5U_14\"^/C\58U3XGNW_``BS)!X/_P"$O0ZX8X]DBM"?/J?2:X)IX/+,
M7+).*O:YOQ#5X>E0Y>>MS4E!RIJE%RE.I)S45&"DY2]U/F:3=FWI;M=NV^SU
M6W5MVLM;-7M_GF^1[_K_`/6HK^]S]DC_`()[_P#!M'_P45NO'_PL_9)\*?$K
M4_B-X"\,/K>LW=QXX_;%\.^)=`TK6O\`B2CQCHR_%_Q)_P`*XF9V_L4(L<4Q
M8A04PJ"OFGXD_P#!-K_@WK_X)A^-)_A7_P`%%OCK\7_C5\6M<74/$_AG0C=_
M'_37\">!6=SHL<D?[/R1@?NU!CE>61BS,'A"Q`2=:^DEP_\`7*F4OA/BI9Q2
M=_\`5K_5^+J2IV3C5C:4FHM6:<^5K72]DYLEV_RVMNEK>VB[;['\7-%?W!?\
M%$/^"$__``3AG_X)[>./VX_^"?.G>./AQ;>#/A9)\:/#<?\`PEWQ-\:^!_BQ
MX!T$G6]9T?7?!?Q<>;XDKYB1^9&S,KA1$)(,EHU^0?\`@CK_`,$D?^";?QU_
M98N/VNOV_P#XSZ-=7.IW?BB]T;X/GX__`/"I])T#PQX';:-:U[^P#X1^);>(
M%`9I%$H**%VJS2`T8?Z1'`N(X>S7B.66\21=/$+#/AK;B".(O%*G=747S633
MLXOW6N9,=F]&NG-?I9>=KZ:=/2Y_)W1Y'O\`K_\`6K^U'X"?#K_@TU_:R^.O
MA?\`9L^#GPI^+\/Q0^(.MCPUX#N]:^(7[8ECH^O>*&5F1='UB;XTS0R$A2P6
M10K@$[0,FOSN_P""Q'_!$C3/V'OVEOV;_!/[,VL^)-:^%_[67C#2O!/@+2?&
MUT/$/CCX;_$PZN/^)-HFMJ$?7O#K!O\`A)9!(%D#[U)8;7;LR/Q]X6S3-WDV
M:97Q)DCSBG[2,>(VK<L5S75DTE9--W5FK-+W>96>Z2:7GJGII:W^&VOY'\W]
M'[K_`#MK^]?XA?\`!%'_`((<?\$P?@=X0\=?\%'?$GQ&^(_B'Q1JD?@\^*[S
MQA\?=+TWQ9XYFTAM<UC2/!7@K]F,IXE59'BG`'BD.NV/>TB*5#;GP`_X)"_\
M&^__``5"^%?Q&OOV%]/^+O@G7_`%V/#7B3Q;H/CW]I--3\">.=;T9==T;63H
MGQ^\0^+O#/B%E4AE;PLLJM@I(T>X-7EU_I(\(O"O%TN$N*YY-&M["7$\*<_]
M7[J?L^;E45)IS]W:_,G!1<[0.KE;=M'I??RNOG?_`#V/X#**_HP_X)V?\$.-
M0_:7_;V_:C_98^/GC;6]&^%/[&7C%_"GQ2O?">B?8M1\=:GK^J./`VC^"M<*
M2+#_`,)5&C>)_&,I563PB8?+=)&A:OU!^./PA_X-)/V3?BGXV_9U^-FG^/[G
MXK?##6#HWCFSM_''[<'B%]"U?1T0A7;P!X@'PX&!K"_*W^IR_P`BM(ZMVY[]
M(7@[!XS+,GRO+.(\ZDH0J3_U=M%*$E%\S<G&,TDT[<U[/962?-9Z;)/2[?7K
MT]+=[].O\1U%?V1?\%/_`/@A%^Q5X3_8:U7_`(*'_P#!.?Q3XJM_`7AGP=X8
M^)Z^']=\7:WXU\"^/?AGKFLDG6?!.M^(A+\3/#NOC^VU=5>9MX+J`I4LWK?[
M)/\`P12_X)Z?%?\`X(S:+^V?XL^$&N77[0NJ?LL>/?BY:>,]-^,WQDL+"S\<
M>'O!VO#1'3P5H7Q)3PP`K:-&2&A^93L<?.%5T_I$\$ULFR?.H4*[G4XGAPS*
MBXI8BFY\EXU:=]*D5).45S2;=HQEL=#34N73R=_=>MGJD_OM;I='\15)DY_<
M3?9;C@6=WCG\O\*^\?\`@EO\"/AS^U!_P4`_9*^!?QJTJY\1_#7XL?$5O#7C
M#P_:^)!IFHW^F+X+\>Z^<G0"OB5,>(M$!9B0`"`2`<C^B;_@K9_P3#_X)-_\
M$]?VG/\`@G\;_P"'7B?X8?LO?%CQ?\0+;]J.X/Q1^,_B^_U+PQH6C;O#\0.M
M_$6?Q-$%\0ONE?PB!XN"I(43<$A;Z+B_QIX;X>S]<(QRCB:6<3I.K!Q2<6E#
MGBHQ^.?,DVE&+5TTVNO/9M75M[/?NEVMUUU5ODS^:/4OV!?VUM(^%5Q^T'KG
M[*GQTT3X,6W@_2O&G_"RCH__`!35CX&UO.-9'S<CQ5K[;LD`@-C;CYJ^-I?)
MBMIYYH/W%M:8%I[GCG)P/7/'?.._^N?\7%_8,/\`P2\OXO'L_B0_\$[[GX">
M%?MMW;7?Q>_X2,?!S.A#06W!?^%K>9M_L51\X\7;6(`+;B/XEO\`@H-IW_!M
M3#^R/\5A_P`$_P#6_&8_:ETNSTL_#:TU:[_;(`.I_P!M1C7MS?%Y1\-&'_"/
MB3NQ``VX.0/S?P\^D-C<_EG>!QW"O$UHUYTJ=7AFE*<8+10?$$I.V4SC9N?L
MU9?#;W7)]'U6RT6_IT71**[:)N[74N?'K_@A=^SC\&?^";&K_MJ:%^VA-XD^
M(FA_!?P+\5V^%:-\-/+O?$>O:KH&DC1VUO09/^$H,`T+QH(0JAY3.RNX:/\`
M>+_,I_RR_P`_W:_M[_:L_P"",G_!/KX6?\$4O$O[9'@_X(>*=)^/>F?LN_"_
MXL6GB^^^-/QC\1_V?XG\=ZMX`;QQ(O@G6_B5)\-L>)_#^MR"13"K.#E%8Q(9
M,;]BK_@@G_P3[^&?["MC^W3_`,%//%OBG6;#5?A_I?Q9\5Z#H/B36OA[X$^&
M?AC6W;_A"P8/A`\7BGQ#KWBCP_KGA\EHY0#+,057:0WE\(>..59-EF=8K.LY
MXGXAJSXMJ</X>@LAP\:OLVH2C0H<DE[7DNH1J5'[24IISERN#;LEHDEMS.\G
MJ]W)V>O=*^WR/XG:/(]_U_\`K5_>'^R?^QK_`,&MO[?WC[4_@5^S%X)^(=Y\
M6DT;4M9EME^(?[9'AK4'TS0\AM;36/$OBE_"VMJ&82`/),V-RA2V&/X&?MY?
M\$BX/V2?^"GOPG_85TOXN6I^&'[0%Y\,?&G@?XE?$C4M$\/IX1^&/B'QAK_@
M775^)NLZ^B^&?$7B'PDV@:\/!3JJ[U:-2D18`_IG#WCQP?F.:YID^.RKB7(<
MW5*5>*XEBDW2IQO*4(VL[=$O.S:BVN7ZM?HFKI7TT;V^SWMUW/PO\GR8OS].
M_3\>G7GKQ1Y/G?N?^?K_`$+/IGO[Y_SC.*_ND_:"_8*_X-H?^";7PY^'A_:7
MN_&W[1'B;Q/JZ>#K/Q%X>^.WQ)\1_$C6M0TC1EU>4Z[HGP!^(_PJ\,:!H<).
MB-&[001LTMO&K*X:5.V^!_\`P1K_`."%?_!5+]F[QM\1_P!@#2OC/\&+WPUX
MDU3X?67BB;QE\8/$#>&?B6G@SP_X@_L?Q#HGQA\2_%+PQX@T`>'_`!!X+#GP
MO,SB#8([K*)$OS:^DKPAS*MB^%^)(9.ZBI0XF_L.E%-RFHJ7+[3F2ZKF2E9O
M1S5F[6=E;S2NG?MM:_SMW:6I^!G_``1,_P""1_@C_@K+??M*P>,?C!X^^#UO
M\'3\(/$J:1X>\.Q:DVH'XJZMX^<ZNNLR.HR?^%6'80!ABSE@%+)^:_\`P4`_
M98T3]B_]L#XW_LP:'XJUSQKH_P`'/%X\'6GBKQ%I"Z;]NSHG]O8)5F0D%@"5
M+#DD$KS7];__``:5>`_$'PT^,/\`P51^&GBE(+7Q/\-?$G[.?@KQDK:1_8!?
MQ)H/B_\`:=B75O5%\4Z$4D7;A@BA,[&)/SY+_P`$P_A__P`%-_\`@X-_X*$^
M!?C1X@\2>'_A'\)[K3?'_B[2?#-ZNE>(_%G]NZGX>T30]"&LE"8]"\2HLLDA
MC9W50"BH8RS?'Y9XSXS*O%#CW&XSB6<^#LGX9]M1I\D97BH4%&"C%<_-*I.2
M2M*3DY)6248I8=6C;EYF[;[.\GO9NR2LVD[;VM>W\<G_`"R_S_=JQ7]M_P"V
M=\(?^#6_]A'XW:]^S9^T%^S]\?/$/Q=\+6NF:UXOMO#_`(X_:KU`V-CXY5?'
M.CZQNC^-?A3PT4VZU'(D?A7PU+L\TDJCLYD^:O\`@H7_`,$VO^"(>M?L5^+?
MVF_^">_[3OPV\`_$[0?AO8?&;P[\']>_:BTCX@:IX[\-*JKK7@__`(5=X^^(
M]Y\2]!\?2N7\/J&G\R/Q>8K8IYWFM']SD?TC<ES7'913QG#'$F1Y;GU54*7$
M4LCIRR*K-R4(<BA*=W5W7*[J+YI<JC.SULVK.R;:5WHEKNDKWTULK]=K_P`C
MM)-_JI_I_4TM)-_JI_I_4U_0&,:=*HT[ITY-.UKIQG9VZ770#_9*_8M_Y,Z_
M9-_[-H^!'_JK?"M%'[%O_)G7[)O_`&;1\"/_`%5OA6BO\=\Q_P"1ACO^PS%?
M^GYGO0^"/^&/Y(_QMJ6;_4GZ#^5)17^Q4US0G%;RC)+YIH\$_P!9C_@F'KU]
MX)_X(U_L<>-8(8-1U#PM^Q5\,/&6EBY[2I\,(9D5CC*CR]P*\!U8@GH!_)':
M_P#!X=^W?-;6]Q_PS1^QZOVFUSM%I\8P!Q@*0?B-DKQ]TD]!GIBOS6^''_!>
MC_@I-\$?@7X>_9&\.?%#X:Z#\//`'P_C^#VA^$+WX(>#/$&K#X=?V,+812>,
M#*"9O[`80["A=F5`R[T79^-D-F((K?R?^7;U[_3^>!_2OY(\/OHYY5/B3Q!Q
MW'^5PSAYSB:U7A=8>O5BN65:<XNJH*BU4=.4)5(/VD>=S7--)2D?6HO2+3:2
MC).S]ZT6U;GE;I9.SM9VU/Z#OVJ?^#E'_@I+^TS\._$'P>?4O@3\"/"'CFV\
M=:1XMU7X,>#O&">);_PP52(QKXY\=?$3XK*@QO8O\*V1@&D"2JI1%_K._P"#
M8F'R?^"07PZ7/_-4/CI]1G7)>W7MGG^E?YD=?KM^RO\`\%KO^"B?["/P'LO@
M=\`O'/PX\-_"?0?$7B&\T#3_`!!\)/!OB#41J4Y8^+VDE!`597D8Q%SB7<PC
M;YB1[GB7X$2Q_`]+AO@+*.',FY>**?$E7VE6<9SA""BU4JN-6<I[:R]Z^O-H
M@3LVVW:RV2NK6>BTCK:]WU\K6^!/V'N?VH?V2#Z_'GX.?^IKX!K^];_@[Y@6
M7]@/]F:WER;:Y_;A\`6=V<\;6^"GQ[((&>A);CKQR:_SV?ASXJ\5_"_QIX#\
M:>`]3-CXF\!>+/#FO^'9+GYU3Q';D-X-D9E^4+#M'FN6"Q#(<@D&OT>_;9_X
M*Y_MS_M]?"CPS\*_VLOB#X3\7?#KP)\0]*^)FDV]G\+_``?X)U%_$8\*>-_#
M*;Y?`1^:/_A!?$/B^/+G_CXEA0D2NE=/B!X4\0<0<6>'&<Y3&C_9G#N'G2XD
MJSDXRI2G&@G*G:+]U\CO=PM:/+=-M)8F*C)-V6B6UG:VK?-I:]DNNI_?CXF\
M!^#O^"4/_!.73OB=_P`$]/V']"_:0^)'ACX=?##3K7P7\)O!Y_X6/\:M-UJX
M\$1ZS\1_&>N^`_A]XP^(WCR>+][\2;UEC,DI`WM#Y42Q?.'_``2__;Q_:R_;
M+_:BG;]I;_@D1K'[*]YX9\`>*=5\,_M)^)O@_P#$?X?+H>KG6(4UOX=2>-?B
M%\-X)''B94>5XK:ZA:15N28VF,3#^/?]FS_@O7_P4X_9"^%7@SX??#WX[:'X
MG^%WA33/[/\`"'A_XW_"SPAXQ7P[H:^6!X9\/>.=$V_$B[@95*I/XFD9$VCY
MT4!7]1OO^#F#_@KWKWC'PWJL?QX^'.ASY/\`97@S2_@?X.7PWXD$H8$>+79A
M,Y.2%:VER@^[C`K\9Q7T=N/T\VP*RKAK./[:JU)TN)'Q%6BHQG*7)[2CS*+F
MT[-351<RWJ<SN?6X7[?"FGRIWO9:N5[76EFFVE;2S/WH_P""B^3_`,'3W_!-
ML#[Q^#GP>QGIG_A9OQ\Q_2O"?^#R&'_B<_L`@Q9/V3X\9ZD@_P!L?"#@\CW]
M.N3CG/\`.1\3?^"J7[:OQA_:Z\"?MU?$KQAX:U+]H#]G?PSX<\&:'XOT?X?^
M#M+\'^'X[?6?'>O^$!KO@H*W_";>5KVO22M(RXMD0LXRJE^._;O_`."E?[6G
M_!0"7X8O^UYXM\(^*)_AB?$T7PZN[+X7^#_!K:-IGCD:#_;0<^`29)79;;1"
M/,W.QA);+(<?:<$>!_%_#_&'A]G6-7#;RG(*,:7$=ZTY6E%S3:]R,:EU-7J.
MUY722LVSZU"S7GNTDOLWUYGM;IHWUT=O([G]K+]J?Q#X5TCX+>*?VH/VAM;^
M"UT-*\&?\*SNOC!XRU'X:-X7T35U*^#?^$'?XBK\,RK`!E!4'9@`\YK_`$%_
M^"_$0_X<$>,%)SCPE^RFQ^G_``D7@+`''H<'U/-?YIT/[BZMKZ#_`(^+4_;!
MGZ]/K[#CZ<&OU>_:$_X+0_M__M@?LYZI^R=\4_'_`,-O&'PCU>T\&66J:7HO
MP8\'>#O$3Z=X#GT1O!^-=C;:72:+2-_\<(20`HNZOTWQ(\(,TS[B_P`/LWX9
MI\,QR?).)9\1\2Q7[NZJ3I3E:"A:4G[/FNTMK-ZMH6)BDHMK7KI=M+MS:WUO
M;;?R?ZS_`/!GW_R>]^TI[?LM$_G\9-"'X]>E?)7_``=$'R?^"MOQ(Y'_`"0?
MX.#_`-/W'?T_IC-?F-^P_P#M[?M'_L"^-_&WQ._9.\8:5H/C'Q]X#7P;X@U3
M5OAYX.\:,=+T?QAH#*4'CLDY<%0`O.2N<;25\_\`VO?VLOCI^V+\;M>^-W[1
M/B73=2^*FM:/X6\+:QJVE^!O"'@L7FEH"$#MX$^\P7)&YF.#@\Y%883P_P"(
MUXT9WQTE061U>&_[`A.,I.:J>QI4T^1TE!)*FY*:J.3O%65VP^LQ:5K7]/=M
M=M-2YNSVM\S_`$/?"S)!_P`&T,TO_+(_\$]]6_`#1-<+9'_?&.N1P#Z\#_P1
MH_9E^!/[,G_!([X6?M3?`C]G?2/CC^T=XP^"'BGXLZQ=Z3H\*_%WXL>*AK&O
M/HGPVT+QQ)&6T$`:1'X7'AD,\.]&C=$*GS?XSXO^"VO[?/AG]EE?V)S\1/AW
MIGP5D^$NI_"&[\(GX+^#]2\3-X(UZ/74UF-?&)(`E*L?E`_>;@0H9-QYW]BG
M_@KW^WY^PIX-L?AC^SG\;[X_#_Q%?2>(]`\!>-/!'@OXC:)<:G\T<J:!KGCH
MCQ#X*B;&"D9DA)17*LX5A^*8CP$\0,5E?%F%P>8X537%U7B6E3]M4A'B'"2G
M&*4ZD::E"?+)U)P490C/W%/55(OZS"Z5^G]UNZ:3LN:W*MKWNM+K6Q_7C^RO
M_P`%-OV\/VP/VJO@=\-?VD?^"(?BWP#\.+WQQIX@^,'B[X,?&"QD_9YUC15U
MV./XE#QK\6O@O;?#D/X6>16B;PU<6TLK:Z5BNE;(KI_^#@SQ[HG@3]JO_@CG
MXQ\1WEMI?AWPO^UO]MU>[NB#]C4HFAEN,?Q$C'^SGO7\S?B#_@Y@_P""N_BR
M72KO3_C;X#\)V.E78N[Q?"_P)^&LYO2",B1=?$C,",C`V')!)/2O@O\`;M_X
M*E_MD_M_I\/-%_:T^(?A;Q%:?"36=5U_P1?:3\/-#\#:A%JSZ0`7F;P%P-V1
MR74`L#NX('H9%]'KC]\491FN.RSAO(\H4)Q:7$52K&//%QC*+JIS>DXN:]Q7
MBTHM.*!XJ/O7UNU9M17\O:;22MUU;VMI?^V#_@Z._9)_:4_:K_9U_9ON_P!G
M#X->//C1?_#OXO>,]8\9>%_AOX0?QIXTL=(\0_#EO#T>LZ1HB!I9%#*0R1@R
MDLAC#2,JM^'G_!*+_@WI_:?_`&D/#GQ3\6?M">*/VE?V"4TC6],7P)H^K_#?
M_A&O$GB\#26+:Q)X)\=&.70OG^1B'61!E`RB,;?A'X`_\'"7_!4O]FS1=&^&
MN@_'O2OB%X>\.>&H]*\'>%_C9\,/!WCB6WTI"S0Z</&.@GPG\369%1%$_BCX
ML^+\K%&"0RJ1U/Q5_P"#D3_@K5\1/#.L^%+WXW^`?AGINI6NHV>KZE\,/@UX
M./B6[`!1BNJ^(-YB+(Y7?$(VP3NWYP/7R7PU\<N%\BS3@+(,;PI_8;Q,I2XC
M4G4FJ4ZRFYP52BXJHZ<V_9.-DVHQKR^(EXB#N[-Z+3W4[VMI^\]UI?:NFTT[
M)Z']&'_!NQX+\'?`[]KC_@J[^RGI?Q+U/XF^(?AA\5/"YM/B1XC*_P#"3^//
M#&B*V@_\)?K9#,I9?$G]M@$.P)S\Y&&KT?\`;7_X*)_\%;_@#^TQ\5?A3\(_
M^"/%A\?_`(5:1XLU(?"_XO>'?A5\8?&NE^.O`A+!)-<UOP#X=?P]H'B-U'61
M@`5/RNREV_@A^`7[1W[0_P"SI\6=-^-OP.^*'C/P!\7K+5=1MY?&NCW&CZIJ
M=YJ&O9UG6SK^B>(0_AO7$D);_6,J2L,L2P45^T<'_!T+_P`%;_".CR67B#XD
M_!?6)K5A9/XD\7_`OPG#XBO.`>=)\!R1>&8B".F%4C/S')!Y>*?`#C.'%>/X
MAP,N&N,X3X=IU*KXBJ5N'W&4:5.#=)9!:+:E%6]ZG#>4HR;E<6*BDKZ:=DU:
MROS-Z*U^^MOB2NC^FW]N[QK_`,%/?%O_``2M_:#\<?M`_#K]ACX(?#OQ!^S,
M\_COP!&?C"_Q-\#/K+:.NN:!*==S\-6,+MI<<<;91)2ZL#*!CV[_`();^&]6
M^)'_``;X_#CPAX!M&UKQ+XI_8^^)?A;PSI-K@:A?^*SX.\1:%H>C9X)=_$>U
M,$D9V!>6.?X3_P!L/_@L!_P4/_;]\&6_PT_:#^-UOJ7P\O81J:_#CX?>`_"/
M@SP)JLVBN6&I^,I0C>(_$$B\X@>3[K?NX\@*,3]BK_@JY^WW^PKX-N/"?[,O
MQ=;1_@]J]_=3S?#KQSX2\)?$/X:P:O#M:]U/P_I'B,CQ%H1UYHE^U1P[2F5\
MTOM4Q^=2^CQQZN!OJ>$7#.4YPN*8\34Z?--0A%4Z<53]LXRG)<T>95.7F7-'
MFNXN0_K<>9:-=+V6ZU4E[S7+K%:.RUV5TOTI_P"")'_!+'_@H%X*_P""DW[,
M'Q,^)G[)WQJ^$OP[^!GB^3Q%\1O&GQ7\"-\./#L>G+X)\=Z(-(T(2@Q?$!F\
M0:UA?%".Q"1MYBJNT-^E'_!X]N^S_L3%E^T'R/C'R"""/(\-<Y&/IGVXK\5O
M'?\`P<9?\%>?B)J.CZI_POWP_P"`[?P+J_\`;*Z#\,_A#\.;/3-6NP,"S\1_
M\)!YKZSHP`_X]FQ)N);82S,?C7]NG_@I'^UY_P`%"=2^&NE?M;>,/"OB;_A5
M][XD;P8UI\.?"?@TJVO)''K)G;P&6(9DBC`+'Y]JMDL#7V&5^&7BKFWB'DW&
M'%_^K%LDI3IU8PK3E#V:C)4I<KHQ567O7DVZ;BM/WCLV+$02<5K=W3<4M[7N
M^9VLE9+5OJ[NY_?E\3_!'C#X^?\`!NSIO@_X3>&?$WQ(\<?$#]A3X7'P7X0\
M)67]H^)?%KBW\"ZZ5T711A7U\HAD"D960!B2-BI_,1X;_P"#=6XT[_@F7XW_
M`&W/VF/BW\6/V?/BIX.^%GQ-^(6L?`'Q7\)5T[3-!DT`W"^#-!UZ/QZP\4)X
M@\3-#H"NQ`.^98E8-')C\^?V7?\`@N7_`,%'OV%/A;HWP=^$OQ>T74OAKX4L
M_M?AOPS\7_!FD?$.WT#2Y-8,97P=KBO'XAT+PZ3LV>&97Q#\[(,ME<K]L#_@
MLO\`\%'OVX_AOK/P\^.GQET6'X.7U_HH\2^!?@]\//"GP_\`"_BR2=0UGJ?B
M?Q%(6^)6KS:([!8_"LLH\*71A5F5Q'"6\')/"7QJX:SG.<%PYFG#-+)L^XHE
MQ+*=.:E5E3E=^SE"IAY)4Y+W&E.ZLG"2>C'B8=KM)77KU]V:?1VT;;6SN?VR
M?M\_:!_P;.>*_)B!G/[$'P'"CH<_VI\)R!^A.>O'7O71_MH_#OQ9^V!_P;TZ
MOX/_`&8M%U3XH^+_`(F?LI?`76OAKX8\+W;S:CXUTS1?%_P[\;O#H?`75]=E
M\.^'M6D6(,/M%RS\;Y%S_#AXZ_X+8?M\_%?]EB\_8P\:>//AEJGP)USX8>&?
MA;J6D6?P6\(:?XDM?!'@4>'=;T2)-94[)9%"(I5%W*0Q"AG;.;^Q3_P5U_X*
M._L/^#--^$W[-?QIU6W^&Z6&H^*=,^#_`(R\(_#KXA^"M(T>3+/K?AG7_&X/
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MGD1OEGQ-_P`'07_!6[Q'IDUE;_$OX,^!K8VV^ZU;0?@YHT^J!N@,32R2["<D
M?)QSTK\<?&'[1?Q^\7?M!0_M#^+?BI\0]6_:5A\;:7XTMOB/?^)!?>)])\;:
M(S:W'K7@W6V$8\.^'0"NWPQCRL;$Y`*#]'AP#XY\29GFO^L6;\,Y#EDL-4I1
MCPY&FZ;JSA:E.55THUURR:;M4@FU'2ZO)_681LK<RNFV[7T>R]ZUV]KKYZ:_
MZ27_``4T_;#_`&A?^";>D_"SX9?L0_\`!+6Y_:$\`>*-':S\0ZK\,OAOXTU/
MX;^`],T0JFBZ+K'@CX0?#BX"MEGEC#-'$D`\L+Y@"R?0/_!(_P",OQ3_`&@_
M@AX^^+WQF_8"N/\`@G_\3/$WQHU&R\2^![GP'K7P^G^*PA\&^`QI/QGDT?Q'
M\._"7BJ9KB`IX31O$R/*I\#&1I7>0+'_``Z^!_\`@YK_`."N6@:59^'4^*WP
MQ\<:A9VJZ5!JOBGX.>$3XB21"0FJ:SJZ.$UB4`D,H"R.!\V<`'+LO^#E?_@K
M]HVH^)VD^/OA?6UN-8U&[O['5/@#\'?L.A6":42L>B+"`_R@AFB<L&&_)8N8
MJ_)\3]&CQ,67?V0LJX8>8.M[1\1RXDKR]K%R7+&5%Q]G%."][W*G,FHKD4$P
M^LP7?XNB6B]4VWY/2SWLKI?T/_\`!MWN_P"&^/\`@NYB$A?^&D/`H8=-V?C-
M^UWCWX`SD=..,5\W_!?P_P#M<W7_``<8_P#!37Q1^QMXV_9TTWQIX3TO2;GX
MA^`?VBK#XEV'@;XC?#%M!^$I;7-&UGX?Q2%?$/A/XBC0PLLA6*,@JX;>=O\`
M.'^R7_P5U_;7_8N\?_M,_&WX):W\.+/Q7^U?XYT[XB?&;7O&OPM\)WNG:KXG
MCUCQYX@T9]!T'0&4Z*JZ_P"/?&<K[`T2I+$Q"[Q7DMQ_P4*_:Z?]M?Q-^W9X
M'^*5U\/OVG/'-[_PF=_XL^%FD:3H/AW5?#NK1C0C::MX(U\2Z!XFL]FWS-#\
M4^9#(0'DE8JK+];A?`?CVOFW%F+?^J_+GO#E+((\]24[SI0PT914/9+D3]E)
MJ<*DWS3=3D<FXI/%02C=I/56TB]WJK3O-ZK2VJ]W5;_W5?M9_P#!5S]O[]F/
MXTZO\%?%O_!%WQW^UE9Z%8>&M7TWXN_`BY^-'B+X8^+-1UU()]5T;0BO[&?Q
M5\N;PH3*)8W\3"4)X&C99B";=NW_`&HOV9/V;OV__P#@E/\`$G]H3]HS]@OP
M[^R-\:6_9D^,/Q-\/Z3XJ\'Z1X>^-O[-WB7P1X2\=:OH4VK^+?#_`(6^%OB]
MO#D%QI,'BJ;POXM2&V\66MQYE[X/*Q*!_*Q!_P`'1/\`P5QT&SCL]5\?_`6X
M-JXTV35O%_P7TTW]W.%_Y"13P,XBAD"CYD0+DY.&))KY(_:R_P""T7_!2_\`
M;D^&.M>`?C/\=IH?@_XFCGG\4>`_A;X/\&_"GPKXAM$<G3-,U;Q!X>0_$CQ-
MX6,B(\OASQ).T)9092QPR^-E7T=O$?\`M3**N$R[AO(?[%K4ZM;B*EQ'GU2$
MO9RBVZ="I%TH<[BO:15*"E=IRYI:OZU#FM\5U:,&E>S=FW9IV6MF]%INVD?D
MC<*+?[?]A-SJ1_M74M(L[K2@1IE_IFB8(UD=0<JP<'@%3DX/!CF_U4_T_J:7
MR?W7^<=/KGIW_3-+-_J3]!_*O[EQ491P\HRDI2C1:E);-J$DVO)M-J]W;J"\
MW<_V2/V+?^3.OV3?^S:/@1_ZJWPK11^Q;_R9U^R;_P!FT?`C_P!5;X5HK_'G
7,?\`D88[_L,Q7_I^9[\/@C_AC^2/_]D_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
